

10/536,729 YONG CHU 05-18-2006

\$%^STN;HighlightOn=;HighlightOff=;

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptaylc1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 JAN 17 Pre-1988 INPI data added to MARPAT
NEWS 4 FEB 21 STN AnaVist, Version 1.1, lets you share your STN AnaVist
visualization results
NEWS 5 FEB 22 The IPC thesaurus added to additional patent databases on STN
NEWS 6 FEB 22 Updates in EPFULL; IPC 8 enhancements added
NEWS 7 FEB 27 New STN AnaVist pricing effective March 1, 2006
NEWS 8 MAR 03 Updates in PATDPA; addition of IPC 8 data without attributes
NEWS 9 MAR 22 EMBASE is now updated on a daily basis
NEWS 10 APR 03 New IPC 8 fields and IPC thesaurus added to PATDPAFULL
NEWS 11 APR 03 Bibliographic data updates resume; new IPC 8 fields and IPC
thesaurus added in PCTFULL
NEWS 12 APR 04 STN AnaVist \$500 visualization usage credit offered
NEWS 13 APR 12 LINSPEC, learning database for INSPEC, reloaded and enhanced
NEWS 14 APR 12 Improved structure highlighting in FQHIT and QHIT display
in MARPAT
NEWS 15 APR 12 Derwent World Patents Index to be reloaded and enhanced during
second quarter; strategies may be affected
NEWS 16 MAY 10 CA/CAPLUS enhanced with 1900-1906 U.S. patent records
NEWS 17 MAY 11 KOREAPAT updates resume

NEWS EXPRESS FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.
V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT
<http://download.cas.org/express/v8.0-Discover/>

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8
NEWS X25 X.25 communication option no longer available after June 2006

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * *

COMPLETE THE STN SURVEY - APRIL 27 THROUGH MAY 31

Dear valued STN customer,

In an effort to enhance your experience with STN, we would like to better understand what you find useful. Please take approximately 5 minutes to complete a web survey.

If you provide us with your name, login ID, and e-mail address, you will be entered in a drawing to win a free iPod(R). Your responses will be kept confidential and will help us make future improvements to STN.

Take survey: <http://www.zoomerang.com/survey.zgi?p=WEB2259HNKWTUW>

Thank you in advance for your participation.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 07:54:18 ON 18 MAY 2006

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 07:54:27 ON 18 MAY 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 16 MAY 2006 HIGHEST RN 884586-69-0

DICTIONARY FILE UPDATES: 16 MAY 2006 HIGHEST RN 884586-69-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*


Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10536729\10536729a.str



chain nodes :

18 19 25 27 28

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 20 21 22 23 24

chain bonds :

1-7 4-20 10-13 14-18 16-19 19-25 22-27 27-28

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-17

14-15 15-16 16-17 20-21 20-24 21-22 22-23 23-24

exact/norm bonds :

10-13 13-14 13-17 14-15 14-18 15-16 16-17 19-25 20-21 20-24 21-22 22-23

23-24 27-28

exact bonds :

1-7 4-20 16-19 22-27

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12

G1:O,N,Hy

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom

11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS 19:CLASS

20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:CLASS 27:CLASS 28:CLASS

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS


L1 STR

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

Structure attributes must be viewed using STN Express query preparation.

=>

Uploading C:\Program Files\Stnexp\Queries\10536729\10536729b.str



chain nodes :

```

18 19 25 27 28 30
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 20 21 22 23 24
chain bonds :
1-7 4-20 10-13 14-18 16-19 19-25 22-27 24-30 27-28
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-17
14-15 15-16 16-17 20-21 20-24 21-22 22-23 23-24
exact/norm bonds :
4-20 10-13 13-14 13-17 14-15 14-18 15-16 16-17 19-25 20-21 20-24 21-22
22-23 23-24 24-30 27-28
exact bonds :
1-7 16-19 22-27
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12

```

G1:O,N,Hy

Match level :

```

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS 19:CLASS
20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:CLASS 27:CLASS 28:CLASS 30:CLASS

```

L2 STRUCTURE UPLOADED

=> d

L2 HAS NO ANSWERS


L2 STR

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

Structure attributes must be viewed using STN Express query preparation.

=>

Uploading C:\Program Files\Stnexp\Queries\10536729\10536729c.str



chain nodes :

18 24 26 27

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 19 20 21 22 23

chain bonds :

1-7 4-19 10-13 16-18 18-24 21-26 26-27

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-17

14-15 15-16 16-17 19-20 19-23 20-21 21-22 22-23

exact/norm bonds :

13-14 13-17 14-15 15-16 16-17 18-24 19-20 19-23 20-21 21-22 22-23 26-27

exact bonds :

1-7 4-19 10-13 16-18 21-26

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12

G1:O,N,Hy

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS 19:Atom
20:Atom 21:Atom 22:Atom 23:Atom 24:CLASS 26:CLASS 27:CLASS

L3 STRUCTURE UPLOADED

=> d

L3 HAS NO ANSWERS

L3 STR

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 07:55:41 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 11 TO ITERATE

100.0% PROCESSED 11 ITERATIONS

2 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 22 TO 418

PROJECTED ANSWERS: 2 TO 124

L4 2 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 07:55:49 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 301 TO ITERATE

100.0% PROCESSED 301 ITERATIONS

64 ANSWERS

SEARCH TIME: 00.00.01

L5 64 SEA SSS FUL L1

=> s l2

SAMPLE SEARCH INITIATED 07:56:10 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 28 TO ITERATE

100.0% PROCESSED 28 ITERATIONS

7 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 243 TO 877

PROJECTED ANSWERS: 7 TO 298

L6 7 SEA SSS SAM L2

=> s l2 full

FULL SEARCH INITIATED 07:56:17 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 535 TO ITERATE

100.0% PROCESSED 535 ITERATIONS

184 ANSWERS

SEARCH TIME: 00.00.01

L7 184 SEA SSS FUL L2

=> s l3
SAMPLE SEARCH INITIATED 07:56:28 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 8 TO ITERATE

100.0% PROCESSED 8 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 8 TO 329
PROJECTED ANSWERS: 0 TO 0

L8 0 SEA SSS SAM L3

=> s l3 full
FULL SEARCH INITIATED 07:56:37 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 187 TO ITERATE

100.0% PROCESSED 187 ITERATIONS 4 ANSWERS
SEARCH TIME: 00.00.01

L9 4 SEA SSS FUL L3

=> file caplus
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 501.70 501.91

FILE 'CAPLUS' ENTERED AT 07:57:09 ON 18 MAY 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 18 May 2006 VOL 144 ISS 21
FILE LAST UPDATED: 16 May 2006 (20060516/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l9
L10 1 L9

=> s l7
L11 4 L7

=> s l5
L12 4 L5

=> d ibib abs hitstr tot

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptaylc1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 JAN 17 Pre-1988 INPI data added to MARPAT
NEWS 4 FEB 21 STN AnaVist, Version 1.1, lets you share your STN AnaVist
visualization results
NEWS 5 FEB 22 The IPC thesaurus added to additional patent databases on STN
NEWS 6 FEB 22 Updates in EPFULL; IPC 8 enhancements added
NEWS 7 FEB 27 New STN AnaVist pricing effective March 1, 2006
NEWS 8 MAR 03 Updates in PATDPA; addition of IPC 8 data without attributes
NEWS 9 MAR 22 EMBASE is now updated on a daily basis
NEWS 10 APR 03 New IPC 8 fields and IPC thesaurus added to PATDPAFULL
NEWS 11 APR 03 Bibliographic data updates resume; new IPC 8 fields and IPC
thesaurus added in PCTFULL
NEWS 12 APR 04 STN AnaVist \$500 visualization usage credit offered
NEWS 13 APR 12 LINSPEC, learning database for INSPEC, reloaded and enhanced
NEWS 14 APR 12 Improved structure highlighting in FQHIT and QHIT display
in MARPAT
NEWS 15 APR 12 Derwent World Patents Index to be reloaded and enhanced during
second quarter; strategies may be affected
NEWS 16 MAY 10 CA/CAPLUS enhanced with 1900-1906 U.S. patent records
NEWS 17 MAY 11 KOREAPAT updates resume

NEWS EXPRESS FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.
V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT
<http://download.cas.org/express/v8.0-Discover/>

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8
NEWS X25 X.25 communication option no longer available after June 2006

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * *

COMPLETE THE STN SURVEY - APRIL 27 THROUGH MAY 31

Dear valued STN customer,

In an effort to enhance your experience with STN, we would like to better understand what you find useful. Please take approximately 5 minutes to complete a web survey.

If you provide us with your name, login ID, and e-mail address, you will be entered in a drawing to win a free iPod(R). Your responses will be kept confidential and will help us make future improvements to STN.

Take survey: <http://www.zoomerang.com/survey.zgi?p=WEB2259HNKWTUW>

Thank you in advance for your participation.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 07:54:18 ON 18 MAY 2006

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 07:54:27 ON 18 MAY 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 16 MAY 2006 HIGHEST RN 884586-69-0

DICTIONARY FILE UPDATES: 16 MAY 2006 HIGHEST RN 884586-69-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10536729\10536729a.str

L1 STRUCTURE UPLOADED


```
=> d
L1 HAS NO ANSWERS
L1          STR
*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
```

Structure attributes must be viewed using STN Express query preparation.

```
=>
Uploading C:\Program Files\Stnexp\Queries\10536729\10536729b.str
```

```
L2          STRUCTURE UPLOADED
```

```
=> d
L2 HAS NO ANSWERS
L2          STR
*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
```

Structure attributes must be viewed using STN Express query preparation.

```
=>
Uploading C:\Program Files\Stnexp\Queries\10536729\10536729c.str
```

```
L3          STRUCTURE UPLOADED
```

```
=> d
L3 HAS NO ANSWERS
L3          STR
*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
```

Structure attributes must be viewed using STN Express query preparation.

```
=> s l1
SAMPLE SEARCH INITIATED 07:55:41 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      11 TO ITERATE
```

```
100.0% PROCESSED      11 ITERATIONS      2 ANSWERS
SEARCH TIME: 00.00.01
```

```
FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:   22 TO      418
PROJECTED ANSWERS:      2 TO      124
```

```
L4          2 SEA SSS SAM L1
```

```
=> s l1 full
FULL SEARCH INITIATED 07:55:49 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      301 TO ITERATE
```

```
100.0% PROCESSED      301 ITERATIONS     64 ANSWERS
SEARCH TIME: 00.00.01
```

```
L5          64 SEA SSS FUL L1
```

```
=> s l2
SAMPLE SEARCH INITIATED 07:56:10 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      28 TO ITERATE
```

```
100.0% PROCESSED      28 ITERATIONS      7 ANSWERS
SEARCH TIME: 00.00.01
```

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 243 TO 877
PROJECTED ANSWERS: 7 TO 298

L6 7 SEA SSS SAM L2

=> s l2 full
FULL SEARCH INITIATED 07:56:17 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 535 TO ITERATE

100.0% PROCESSED 535 ITERATIONS 184 ANSWERS
SEARCH TIME: 00.00.01

L7 184 SEA SSS FUL L2

=> s l3
SAMPLE SEARCH INITIATED 07:56:28 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 8 TO ITERATE

100.0% PROCESSED 8 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 8 TO 329
PROJECTED ANSWERS: 0 TO 0

L8 0 SEA SSS SAM L3

=> s l3 full
FULL SEARCH INITIATED 07:56:37 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 187 TO ITERATE

100.0% PROCESSED 187 ITERATIONS 4 ANSWERS
SEARCH TIME: 00.00.01

L9 4 SEA SSS FUL L3

Not ODP


L12 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 2006:342903 CAPLUS
 DOCUMENT NUMBER: 144:390904
 TITLE: Phenyl-substituted oxazolidinone derivatives and their preparation, pharmaceutical compositions, and use as antimicrobials
 INVENTOR(S): Das, Biswajit; Ahmed, Shahadat; Yadav, Ajay Singh; Ghosh, Soma; Gujrali, Arti; Sharma, Pankaj; Rattan, Ashok
 PATENT ASSIGNEE(S): Ranbaxy Laboratories Limited, India
 SOURCE: PCT Int. Appl., 145 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006038100	A1	20060413	WO 2005-1B2971	20051006

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SN, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW


RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPL. INFO.: US 2004-616964P P 20041008




AB The invention relates to phenyl-substituted oxazolidinones I, or their pharmaceutically acceptable salts, solvates, esters, enantiomers, diastereomers, N-oxides, polymorphs, prodrugs, or metabolites, as well as processes for their synthesis. In compds. I: A is pyridine-2,5-diyl,

L12 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)
 difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinylmethyl]- (9CI) (CA INDEX NAME)



RN 883230-18-0 CAPLUS
 CN Acetamide, N-[[[5S]-3-[[4'-[4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl]-2,3',6-trifluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinylmethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORM4T

L12 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)
 pyrimidine-2,5-diyl, furan-2,5-diyl, thiophene-2,5-diyl, and analogs; U and V are independently selected from H (both U and V cannot be H), lower alkyl, or halo; R is CH2NORF, CH2NOC(OR), CH2NOSORF, CH2NOC(O)NHRF, heterocyclyl, or heteroaryl; Rf is H, alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, aryl, aralkyl, heteroaryl, heterocyclyl, heteroarylalkyl, or heterocyclylalkyl; R1 is arido, MCS, MHRF, NR(C17)NRFR, NRFR, NR(C17)OR, NR(C17)OR; Y is (C:O), (C:S), or SO2; T is O, S, N(CN), N(NO2), CH(NO2);

Rj is H, alkyl, alkenyl, cycloalkyl, aryl, aralkyl, heterocyclyl, heteroaryl, heteroarylalkyl, or heterocyclylalkyl; Rq is H, alkyl, cycloalkyl, aryl, aralkyl, heteroaryl, heterocyclyl, heteroarylalkyl, or heterocyclylalkyl; Rs is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heteroarylalkyl or heterocyclylalkyl; With the proviso that:

When U is H, V is F, R is NHCOCH3 and A is pyridine-2,5-diyl, then R is a 5-membered heteroaryl ring contg. two or four N atoms (wherein the 5-membered heteroaryl ring contg. four N atoms is linked through an N-atom to pyridine-2,5-diyl and is always substituted); when A is pyrimidine-2,5-diyl and U, V, and R1 are as defined above then R cannot be a 5-membered heterocyclyl ring contg. 2 hetero atoms. The invention also relates to pharmaceutical compns. contg. I as antimicrobials. I are useful antimicrobial agents (no data), effective against a no. of human and veterinary pathogens, including gram-pos. aerobic bacteria (for example, multiple-resistant staphylococci, streptococci, and enterococci), as well as anaerobic organisms (for example, Bacteroides spp. and Clostridia spp.), and acid fast organisms (for example, Mycobacterium tuberculosis, Mycobacterium avium and Mycobacterium spp.). Approx. 100 compds. I were prepd., and are claimed by name. The synthesis of most compds. I and a variety of intermediates is described. For instance, 5-bromopyridin-2-amine was (1) N-protected with BOC, followed by (2) conversion of the bromide to the boronic acid, (3) Pd-catalyzed coupling of the boronic acid with (S)-N-[[[3-(4-iodo-3,5-difluorophenyl)-2-oxo-5-oxazolidinylmethyl]acetamide, (4) N-deprotection with HCl, and (5) cyclization of the freed amine with 2,5-dimethoxytetrahydrofuran-3-carboxaldehyde, to give invention compd. II. I have good activity against

multiply resistant Gram-pos. pathogens like methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococci (VRE), and Streptococcus pneumoniae. Some I have activity against multiple drug-resistant tuberculosis (MDR-TB) strain, while others have significant activity against important anaerobic bacteria. I are also active against MAI sirens and Gram-neg. pathogens like Moraxella catarrhalis and Haemophilus influenzae.

IT 883229-93-4P, N-[[[3-(2,3'-difluoro-4'-[5-(hydroxymethyl)-4,5-dihydroisoxazol-3-yl]biphenyl-4-yl)-2-oxo-1,3-oxazolidin-5-ylmethyl]acetamide 883230-18-0P, N-[[[5S]-2-Oxo-3-[2,3',6-trifluoro-4'-[5-(hydroxymethyl)-4,5-dihydroisoxazol-3-yl]biphenyl-4-yl]-1,3-oxazolidin-5-ylmethyl]acetamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (drug candidate; preparation of phenyl-substituted oxazolidinone derivs. as antimicrobials)
 RN 883229-93-4 CAPLUS
 CN Acetamide, N-[[[3-(4'-[4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl]-2,3'-

L12 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 2004:467906 CAPLUS
 DOCUMENT NUMBER: 141:38599

TITLE: Preparation of oxazolidinone/isoxazoline derivatives as antibacterial agents
 INVENTOR(S): Cifuentes, Daniel Robert; Gravestock, Michael Barry; Sales, Neil James; Hauck, Sheila Irene; Weber, Thomas Peter
 PATENT ASSIGNEE(S): AstraZeneca AB, Swed.; AstraZeneca UK Limited
 SOURCE: PCT Int. Appl., 183 pp.
 CODEN: PIXXD2

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004048392	A1	20040610	WO 2003-GB5087	20031124

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MG, MK, MN, MW, MX, MY, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG


TG CA 2507468 A 20040610 CA 2003-2507468 20031124
 AU 2003302404 A 20040610 AU 2003-302404 20031124
 EP 1567532 A 20050831 EP 2003-811807 20031124

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

BR 2003016688 A 20051018 BR 2003-16688 20031124
 CN 1742015 A 20060301 CN 2003-80109196 20031124
 JP 2006050812 T2 20060309 JP 2005-510253 20031124
 NO 2005002534 A 20050822 NO 2005-2534 20050526

PRIORITY APPL. INFO.: GB 2002-27702 A 20021128
 GB 2003-4725 A 20030301
 GB 2003-18608 A 20030808
 WO 2003-GB5087 W 20031124

OTHER SOURCE(S): MARPAT 141:38599
 GI



II

AB Title compds. (R1a)m-A-C-B-CH₂-R1b [C = biaryl group; A, B = dihydroisoxazole, oxazolidinone; R1a = CN, carboxy, alkoxycarbonyl, aryl, etc.; m = 0-2; R1b = OH, silyloxy, etc.; 1] are prepared. For instance, (5R)-3-(3-fluoro-4-iodophenyl)-5-[(1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one (preparation given) is coupled to 5,5-bis[(tert-butylidimethylsilyl)oxy]methyl]-3-[4-(trimethylstannyl)phenyl]-4,5-dihydroisoxazole (preparation given) (NMP, (furan-2-yl)3P, dba3Pd2) and the resulting adduct desilylated (THF, TBAF) to give II. II exhibits MIC = 0.5 µg/mL against *Staphylococcus aureus*; compds. of the invention are antibacterial agents.

IT 702679-77-4P, (5R)-3-[4'-[5,5-Bis[(tert-butylidimethylsilyl)oxy]methyl]-4,5-dihydroisoxazol-3-yl]-2-fluoro-1,1'-biphenyl-4-yl]-5-[(1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 702679-98-9P, (5R)-3-[4'-[5,5-Bis[(tert-butylidimethylsilyl)oxy]methyl]-4,5-dihydroisoxazol-3-yl]-2-fluoro-1,1'-biphenyl-4-yl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of oxazolidinone/isoxazoline derivs. as antibacterial agents)

RN 702679-77-4 CAPLUS

CN 2-Oxazolidinone,
3-[4'-[5,5-bis[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-4,5-dihydro-3-isoxazolyl]-2-fluoro[1,1'-biphenyl]-4-yl]-5-[(1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

yl]-5-[(1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 702680-35-1P, (5R)-3-[4'-[5,5-Bis(hydroxymethyl)-4,5-dihydroisoxazol-3-yl]-2,2'-difluoro-1,1'-biphenyl-4-yl]-5-[(4-(fluoromethyl)-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 702681-75-2P, (5S)-3-[4'-[5,5-Bis(hydroxymethyl)-4,5-dihydroisoxazol-3-yl]-2,2'-difluorobiphenyl-4-yl]-5-[(1,2,5-thiadiazol-3-ylamino)methyl]-1,3-oxazolidin-2-one
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of oxazolidinone/isoxazoline derivs. as antibacterial agents)

RN 702679-95-6 CAPLUS

CN 2-Oxazolidinone,
3-[4'-[4,5-dihydro-5,5-bis(hydroxymethyl)-3-isoxazolyl]-2-fluoro[1,1'-biphenyl]-4-yl]-5-[(1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 702680-03-3 CAPLUS

CN 2-Oxazolidinone,
3-[4'-[4,5-dihydro-5,5-bis(hydroxymethyl)-3-isoxazolyl]-2-fluoro[1,1'-biphenyl]-4-yl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 702679-98-9 CAPLUS

CN 2-Oxazolidinone,
3-[4'-[5,5-bis[(1,1-dimethylethyl)dimethylsilyl]oxy]met

hyl]-4,5-dihydro-3-isoxazolyl]-2-fluoro[1,1'-biphenyl]-4-yl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 702679-95-6P, (5R)-3-[4'-[5,5-Bis(Hydroxymethyl)-4,5-dihydroisoxazol-3-yl]-2-fluoro-1,1'-biphenyl-4-yl]-5-[(1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 702680-03-3P,

(5R)-3-[4'-[5,5-Bis(Hydroxymethyl)-4,5-dihydroisoxazol-3-yl]-2-fluoro-1,1'-

biphenyl-4-yl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 702680-06-6P, N-[(5S)-3-[4'-[5,5-Bis(Hydroxymethyl)-4,5-dihydroisoxazol-3-yl]-2,2'-difluoro-1,1'-biphenyl-4-yl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]acetamide 702680-23-7P, (5R)-3-[4'-[5,5-


Bis(hydroxymethyl)-4,5-dihydroisoxazol-3-yl]-2,2'-difluoro-1,1'-biphenyl-4-



RN 702680-06-6 CAPLUS

CN Acetamide, N-[(5S)-3-[4'-[4,5-dihydro-5,5-bis(hydroxymethyl)-3-isoxazolyl]-1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinylmethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 702680-23-7 CAPLUS


CN 2-Oxazolidinone, 3-[4'-[4,5-dihydro-5,5-bis(hydroxymethyl)-3-isoxazolyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-5-[(1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 702680-35-1 CAPLUS
CN 2-Oxazolidinone, 3-[4'-[4,5-dihydro-5,5-bis(hydroxymethyl)-3-isoxazolyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-5-[[4-(fluoromethyl)-1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 702681-75-2 CAPLUS
CN 2-Oxazolidinone, 3-[4'-[4,5-dihydro-5,5-bis(hydroxymethyl)-3-isoxazolyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-5-[(1,2,5-thiadiazol-3-ylamino)methyl]-, (5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN 2-Oxazolidinone, 3-[4'-[5,5-bis[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-4,5-dihydro-3-isoxazolyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-5-[(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)




RN 702680-37-3 CAPLUS
CN 2-Oxazolidinone, 3-[4'-[5,5-bis[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-4,5-dihydro-3-isoxazolyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-5-[[4-(fluoromethyl)-1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 702681-77-4 CAPLUS



IT 702680-09-9, (5S)-3-[4'-[5,5-bis[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-4,5-dihydroisoxazol-3-yl]-2-fluoro-1,1'-biphenyl-4-yl]-5-(acetamidomethyl)-1,3-oxazolidin-2-one
RL: RCT (Reactant); RACT (Reactant or reagent)
agents)
RN 702680-09-9 CAPLUS
CN Acetamide,
N-[[[(5S)-3-[4'-[5,5-bis[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-4,5-dihydro-3-isoxazolyl]-2-fluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 702680-25-9P, (5R)-3-[4'-[5,5-bis[[[(tert-butyl)dimethylsilyl]oxy]methyl]-4,5-dihydroisoxazol-3-yl]-2,2'-difluoro-1,1'-biphenyl-4-yl]-5-[(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one 702681-77-4P, tert-Butyl [[[(5R)-3-[4'-[5,5-bis[[[(tert-butyl)dimethylsilyl]oxy]methyl]-4,5-dihydroisoxazol-3-yl]-2,2'-difluoro-1,1'-biphenyl-4-yl]-5-[[4-(fluoromethyl)-1H-1,2,3-triazol-1-yl]methyl]-1,3-oxazolidin-2-one 702681-77-4P, tert-Butyl [[[(5R)-3-[4'-[5,5-bis[[[(tert-butyl)dimethylsilyl]oxy]methyl]-4,5-dihydroisoxazol-3-yl]-2,2'-difluorobiphenyl-4-yl]-2-

L12 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN Carbamic acid, [[[(5R)-3-[4'-[4,5-dihydro-5,5-bis(hydroxymethyl)-3-isoxazolyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]methyl]-1,2,5-thiadiazol-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L12 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 2004:467887 CAPLUS
DOCUMENT NUMBER: 141:23522
TITLE: Preparation of isoxazolinyloxazolidinone
antibacterial agents
INVENTOR(S): Gravestock, Michael Barry; Hales, Neil James
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 78 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE
WO 2004048370 A1 20040610 WO 2003-GB5082 20031124
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NI, NO, NZ,
OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG
AU 2003302403 A1 20040618 AU 2003-302403 20031124
EP 1567521 A1 20050831 EP 2003-811806 20031124
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
PRIORITY APPLN. INFO.: GB 2002-27701 A 20021128
WO 2003-GB5082 W 20031124


OTHER SOURCE(S): MARPAT 141:23522
GI



AB Isoxazolinyloxazolidinone compds. of formula I (R1CH2-A-C-B-CH2R2 [A, B = oxazolidinone, isoxazoline; C = (substituted) biaryl group; R1, R2 = OH, trialkylsilyloxy, acyloxy, heteroaryl, etc.]) are prepared as antibacterial agents. Methods for making compds. of formula I, compns. containing them and their use as antibacterial agents are also described. Thus, II was prepared, and had MIC of 0.5 µg/mL against Staphylococcus aureus.
IT 698981-84-9F 698981-94-1P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic)


L12 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)
RN 698981-89-4 CAPLUS
CN 2-Oxazolidinone, 3-[4'-[4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl]-2,3'-difluoro-3'-methoxy[1,1'-biphenyl]-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 698981-99-6 CAPLUS
CN 2-Oxazolidinone, 3-[4'-[4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl]-2,3'-difluoro[1,1'-biphenyl]-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

Current application


ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)
preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of isoxazolinyloxazolidinone antibacterial agents)
RN 698981-84-9 CAPLUS
CN 2-Oxazolidinone,
3-[4'-[5-[[[1,1-dimethylethyl]dimethylsilyl]oxy]methyl]-4,5-dihydro-3-isoxazolyl]-2-fluoro-3'-methoxy[1,1'-biphenyl]-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 698981-94-1 CAPLUS
CN 2-Oxazolidinone,
3-[4'-[5-[[[1,1-dimethylethyl]dimethylsilyl]oxy]methyl]-4,5-dihydro-3-isoxazolyl]-2,3'-difluoro[1,1'-biphenyl]-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 698981-89-4P 698981-99-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of isoxazolinyloxazolidinone antibacterial agents)

ODP

L12 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 2003:221667 CAPLUS
DOCUMENT NUMBER: 138:238171
TITLE: Preparation of oxazolidinones and/or isoxazolines as antibacterial agents
INVENTOR(S): Gravestock, Michael Barry; Hales, Neil James; Swain, Michael Lingard; Hauck, Sheila Irene; Mills, Stuart Dennett
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 127 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE
WO 2003022824 A1 20030320 WO 2002-GB4120 20020909
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GR,
GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NI, NO, NZ,
OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG
CA 2459766 AA 20030320 CA 2002-2459766 20020909
EP 1427711 A1 20040616 EP 2002-765019 20020909
EP 1427711 B1 20050713
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK
BR 2002012458 A 20041019 BR 2002-12458 20020909
JP 2005507386 T2 20050317 JP 2003-526899 20020909
US 2005107435 A1 20050519 US 2003-489266 20020909
NZ 531621 A 20050624 NZ 2002-531621 20020909
CN 1639136 A 20050713 CN 2002-822327 20020909
AT 299502 E 20050715 AT 2002-765019 20020909
PT 1427711 T 20051130 PT 2002-765019 20020909
ES 2244802 T3 20051216 ES 2002-2765019 20020909
ZA 2004001888 A 20050418 ZA 2004-1888 20040308
NO 2004001428 A 20040608 NO 2004-1428 20040405
HK 1065789 A1 20051230 HK 2004-108506 20041029
PRIORITY APPLN. INFO.: GB 2001-21942 A 20010911
GB 2002-15420 A 20020704
WO 2002-GB4120 W 20020909

OTHER SOURCE(S): MARPAT 138:238171
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB Oxazolidinones and isoxazolines (shown as I: variables defined below; e.g.

FD 11/24/03

PRD 11/28/02


102(e).

L12 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 501940-61-0 CAPLUS
 CN Acetamide, N-[(5S)-3-[(4S)-4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl][1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinylmethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501940-64-3 CAPLUS
 CN Acetamide, N-[(5S)-3-[(4S)-4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl][1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinylmethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L12 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



IT 501939-97-5, (5R)-3-[4'-[5-[(tert-Butyldimethylsilyl)oxy]methyl]-4,5-dihydroisoxazol-3-yl]-2-fluoro-1,1'-biphenyl-4-yl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of oxazolidinones and/or isoxazolines as antibacterial agents)

RN 501939-97-5 CAPLUS
 CN 2-Oxazolidinone,
 3-[4'-[5-[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-4,5-dihydro-3-isoxazolyl]-2-fluoro[1,1'-biphenyl]-4-yl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 501940-00-7P, N-[(5S)-3-[(4S)-4,5-dihydroisoxazol-3-yl]-2-fluoro-1,1'-biphenyl-4-yl]-2-oxo-1,3-oxazolidin-5-ylmethylacetamide
 501940-10-9P, N-[(5S)-3-[(4S)-4,5-dihydroisoxazol-3-yl]-2,2'-difluoro-1,1'-biphenyl-4-yl]-2-oxo-1,3-oxazolidin-5-ylmethylacetamide
 501940-19-8P, (5R)-3-[4'-[5-[(tert-Butyldimethylsilyl)oxy]methyl]-4,5-dihydroisoxazol-3-yl]-2,2'-difluoro-1,1'-biphenyl-4-yl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 501940-20-1P,

(5R)-3-[4'-[5-[(tert-Butyldimethylsilyl)oxy]methyl]-4,5-dihydroisoxazol-3-yl]-2,2'-difluoro-1,1'-biphenyl-4-yl]-5-[(1H-1,2,3-triazol-1-yl)methyl]-1,3-

L12 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 501940-67-6 CAPLUS
 CN 2-Oxazolidinone, 3-[4'-[4,5-dihydro-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-3-isoxazolyl]-2-fluoro[1,1'-biphenyl]-4-yl]-5-[(3-isoxazolylamino)methyl]-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501940-72-3 CAPLUS
 CN Acetamide, N-[(5S)-3-[(4S)-4,5-dihydro-5-(phosphonoxy)methyl]-3-isoxazolyl][1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinylmethyl]-, disodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● 2 Na

RN 501940-90-5 CAPLUS
 CN 2-Oxazolidinone, 3-[4'-[4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-5-[(3-isoxazolylamino)methyl]-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L12 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

oxazolidin-2-one 501940-21-2P, tert-Butyl N-[(5R)-3-[4'-[5-[(tert-Butyldimethylsilyl)oxy]methyl]-4,5-dihydroisoxazol-3-yl]-2,2'-difluoro-1,1'-biphenyl-4-yl]-2-oxo-1,3-oxazolidin-5-ylmethyl-N-(isoxazol-3-yl)carbamate 501940-22-3P, (5R)-3-[4'-[5-[(tert-Butyldimethylsilyl)oxy]methyl]-4,5-dihydroisoxazol-3-yl]-2-fluoro-1,1'-biphenyl-4-yl]-5-(hydroxymethyl)-1,3-oxazolidin-2-one 501940-23-4P, N-[(5S)-3-[4'-[5-[(tert-Butyldimethylsilyl)oxy]methyl]-4,5-

dihydroisoxazol-3-yl]-2-fluoro-1,1'-biphenyl-4-yl]-2-oxo-1,3-oxazolidin-5-ylmethylacetamide 501940-56-3P, (5R)-5-[(tert-Butyldimethylsilyl)oxy]methyl]-3-[2-fluoro-4'-[5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-4,5-dihydroisoxazol-3-yl]-1,1'-biphenyl-4-yl]-1,3-oxazolidin-2-one 501940-62-1P, N-[(5S)-3-[4'-[5-[(tert-Butyldimethylsilyl)oxy]methyl]-4,5-dihydroisoxazol-3-yl]-1,1'-biphenyl-4-yl]-2-oxo-1,3-oxazolidin-5-ylmethylacetamide 501940-65-4P, N-[(5S)-3-[4'-[5-[(tert-Butyldimethylsilyl)oxy]methyl]-4,5-dihydroisoxazol-3-yl]-1,1'-biphenyl-4-yl]-2-oxo-1,3-oxazolidin-5-ylmethylacetamide 501940-68-7P, tert-Butyl N-[(5R)-3-[2-fluoro-4'-[5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-4,5-dihydroisoxazol-3-yl]-1,1'-biphenyl-4-yl]-2-oxo-1,3-oxazolidin-5-ylmethyl]-N-(isoxazol-3-yl)carbamate
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prepn. of oxazolidinones and/or isoxazolines as antibacterial agents)

RN 501940-00-7 CAPLUS
 CN Acetamide,
 N-[(5S)-3-[4'-[5-[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-4,5-dihydro-3-isoxazolyl]-2-fluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinylmethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501940-10-9 CAPLUS
 CN Acetamide,
 N-[(5S)-3-[4'-[5-[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-4,5-dihydro-3-isoxazolyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinylmethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

(5S,5S')-N-[3-{4'-[5-(acetylaminomethyl)-2-oxooxazolidin-3-yl]-2,2'-difluorobiphenyl-4-yl]-2-oxooxazolidin-5-ylmethyl]acetamide (shown as II), or a pharmaceutically-acceptable salt, or an in-vivo-hydrolyzable ester thereof, which useful as antibacterial agents, processes for their manuf. and pharmaceutical compns. contg. them are described. For I: C is for example III, IV, V; wherein A and B = 2-oxooxazolidin-3-yl, 2-isoxazolidin-3-yl; R2a to R3b = H and F; R1a and R1b =, for example, hydroxy, -NHC(=W)R4, NH(HET-1) and HET-2; wherein W is O or S; R4 is, for example, H, amino, (1-4C)alkyl; HET-1 is, for example, a C-linked 5-membered heteroaryl ring; HET-2 is, for example, an N-linked 5-membered, fully or partially unsatd. heterocyclic ring. I have good activity against a broad range of Gram-pos. pathogens including organisms known to be resistant to most commonly used antibiotics, together with activity against fastidious Gram neg. pathogens such as *H. influenzae*, *M. catarrhalis*, *Mycoplasma* and *Chlamydia* strains. The min. inhibitory concns. of II for methicillin sensitive and quinolone sensitive *Staphylococcus aureus*, methicillin resistant and quinolone resistant *Staphylococcus aureus*, *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Haemophilus influenzae*, and *Moraxella catarrhalis* are 0.25, 0.5, 0.06, 0.13, 2.0 and 0.5 µg/mL, resp. Preps. of 64 examples of I and many intermediates are included. For example, I was prepd. as follows: (5S)-N-[[3-(3-fluoro-4-iodophenyl)-2-oxooxazolidin-5-yl]methyl]acetamide (0.4 mmol) and Bu4NBz (0.4 mmol) were stirred in a mixt. of DMF (0.5 mL) and NEt3 (2 mmol), and degassed by bubbling N. Pd(II) acetate (0.04 mmol) was added, and the whole heated at 70° for 18 h. Workup gave the desired product (47 mg). Nine examples of pharmaceutical dosage forms are tabulated.

IT 501939-86-2P, N-[[{(5S)-3-{4'-[5-[[tert-butylidimethylsilyl]oxy]methyl]-4,5-dihydroisoxazol-3-yl]-1,1'-biphenyl-4-yl]-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide 501939-90-8P, tert-Butyl N-[(5R)-3-{4'-[5-[[tert-butylidimethylsilyl]oxy]methyl]-4,5-dihydroisoxazol-3-yl]-2-fluoro-1,1'-biphenyl-4-yl]-2-oxo-1,3-oxazolidin-5-yl]methyl-N-(isoxazol-3-yl)carbamate 501939-91-9P, tert-Butyl N-[(5R)-3-{2-fluoro-4'-[5-(hydroxymethyl)-4,5-dihydroisoxazol-3-yl]-1,1'-biphenyl-4-yl]-2-oxo-1,3-oxazolidin-5-yl]methyl-N-(isoxazol-3-yl)carbamate 501940-39-2P, (5R)-3-{4'-[5-[[tert-butylidimethylsilyl]oxy]methyl]-4,5-dihydroisoxazol-3-yl]-1,1'-biphenyl-4-yl]-5-[[4-methyl-1H-1,2,3-triazol-1-yl]methyl]-1,3-oxazolidin-2-one 501940-43-8P, (5R)-3-{4'-[5-[[tert-butylidimethylsilyl]oxy]methyl]-4,5-dihydroisoxazol-3-yl]-1,1'-biphenyl-4-yl]-5-[[1H-1,2,3-triazol-1-yl]methyl]-1,3-oxazolidin-2-one 501940-69-8P, [3-{4'-[5-[[Acetylaminomethyl]-2-oxo-1,3-oxazolidin-3-yl]-1,1'-biphenyl-4-yl]-4,5-dihydroisoxazol-5-yl]methyl]di-tert-butyl phosphate 501940-71-2P, [3-{4'-[5-[[Acetylaminomethyl]-2-oxo-1,3-oxazolidin-3-yl]-1,1'-biphenyl-4-yl]-4,5-dihydroisoxazol-5-yl]methyl]methyl dihydrogen phosphate

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)


(drug candidate; preparation of oxazolidinones and/or isoxazolinones as antibacterial agents)

RN 501939-86-2 CAPLUS
CN Acetamide,
N-[[{(5S)-3-{4'-[5-[[1,1-dimethylethyl]dimethylsilyl]oxy]methyl

L12 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

1]-4,5-dihydro-3-isoxazolyl][1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501939-90-8 CAPLUS

CN Carbamic acid,

[[{(5R)-3-{4'-[5-[[1,1-dimethylethyl]dimethylsilyl]oxy]methyl]-4,5-dihydro-3-isoxazolyl]-2-fluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]methyl]-3-isoxazolyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501939-91-9 CAPLUS

CN Carbamic acid,

[[{(5R)-3-{4'-[5-(4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl]-2-fluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]methyl]-3-isoxazolyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 501940-39-2 CAPLUS

CN 2-Oxazolidinone,

3-{4'-[5-[[1,1-dimethylethyl]dimethylsilyl]oxy]methyl]-4,5-dihydro-3-isoxazolyl][1,1'-biphenyl]-4-yl]-5-[[4-methyl-1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501940-43-8 CAPLUS

CN 2-Oxazolidinone,

3-{4'-[5-[[1,1-dimethylethyl]dimethylsilyl]oxy]methyl]-4,5-dihydro-3-isoxazolyl][1,1'-biphenyl]-4-yl]-5-[[1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 501940-69-8 CAPLUS

CN

Phosphoric acid, [3-{4'-[5-[[acetylaminomethyl]-2-oxo-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-4,5-dihydro-5-isoxazolyl]methyl bis[1,1-dimethylethyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501940-71-2 CAPLUS

CN

Acetamide, N-[[{(5S)-3-{4'-[4,5-dihydro-5-(phosphonoxy)methyl]-3-isoxazolyl][1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 501939-85-1P, [(5R)-3-[2-Fluoro-4'-[5'-(hydroxymethyl)-4,5-

dihydroisoxazol-3-yl]-1,1'-biphenyl-4-yl]-2-oxo-1,3-oxazolidin-5-yl)methyl acetate 501939-89-5P, N-[(5S)-3-[4'-[5-(Hydroxymethyl)-4,5-dihydroisoxazol-3-yl]-1,1'-biphenyl-4-yl]-2-oxo-1,3-oxazolidin-5-yl)methyl]acetamide 501939-92-0P, (5S)-3-[2-Fluoro-4'-[5-

(hydroxymethyl)-4,5-dihydroisoxazol-3-yl]-1,1'-biphenyl-4-yl]-5-[(isoxazol-3-ylamino)methyl]-3-oxazolidin-2-one 501939-96-4P, (5R)-3-[2-Fluoro-4'-[5-(hydroxymethyl)-4,5-dihydroisoxazol-3-yl]-1,1'-

biphenyl-4-yl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 501939-99-7P, N-[(5S)-3-[2-Fluoro-4'-[5-(hydroxymethyl)-4,5-dihydroisoxazol-3-yl]-1,1'-biphenyl-4-yl]-2-oxo-1,3-oxazolidin-5-yl)methyl]acetamide 501940-01-8P, N-[(3-[2-Fluoro-4'-[(5R)-5-(hydroxymethyl)-2-oxo-1,3-oxazolidin-3-yl]-1,1'-biphenyl-4-yl]-4,5-dihydroisoxazol-3-yl)methyl]acetamide 501940-04-1P,


N-[(3-[2,2'-Difluoro-4'-[(5R)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-1,3-oxazolidin-3-yl]-1,1'-biphenyl-4-yl]-4,5-dihydroisoxazol-5-yl)methyl]acetamide 501940-06-3P, N-[(5S)-3-[2,2'-Difluoro-4'-

[5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-4,5-dihydroisoxazol-3-yl]-1,1'-biphenyl-4-yl]-2-oxo-1,3-oxazolidin-5-yl)methyl]acetamide 501940-09-6P, N-[(5S)-3-[2,2'-Difluoro-4'-[5-(hydroxymethyl)-4,5-dihydroisoxazol-3-yl]-1,1'-biphenyl-4-yl]-2-oxo-1,3-oxazolidin-5-yl)methyl]acetamide 501940-11-1P, (5R)-3-[2,2'-Difluoro-4'-[5-

(hydroxymethyl)-4,5-dihydroisoxazol-3-yl]-1,1'-biphenyl-4-yl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 501940-12-1P,


(5R)-3-[2,2'-Difluoro-4'-[5-(hydroxymethyl)-4,5-dihydroisoxazol-3-yl]-1,1'-biphenyl-4-yl]-5-[(1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 501940-13-2P, tert-Butyl N-[(5R)-3-[2,2'-difluoro-4'-[5-(hydroxymethyl)-4,5-dihydroisoxazol-3-yl]-1,1'-biphenyl-4-yl]-2-oxo-1,3-oxazolidin-5-yl)methyl]-N-(isoxazol-3-yl)carbamate 501940-14-3P, (5R)-3-[2-Fluoro-4'-[5-(hydroxymethyl)-4,5-dihydroisoxazol-3-yl]-1,1'-biphenyl-4-yl]-5-(hydroxymethyl)-1,3-oxazolidin-2-one 501940-15-4P, N-[(5S)-3-[2-Fluoro-4'-[5-(hydroxymethyl)-4,5-dihydroisoxazol-3-yl]-1,1'-biphenyl-4-yl]-2-oxo-1,3-oxazolidin-5-yl)methyl]acetamide 501940-41-6P, (5R)-5-[(1H-1,2,3-Triazol-1-yl)methyl]-3-[4'-[5-(1H-1,2,3-triazol-1-yl)methyl)-4,5-dihydroisoxazol-3-yl]-1,1'-biphenyl-4-yl]-1,3-oxazolidin-2-one 501940-42-7P, (5R)-3-[2-Fluoro-4'-[5-(1H-1,2,3-triazol-1-yl)methyl)-4,5-dihydroisoxazol-3-yl]-1,1'-biphenyl-4-yl]-5-

Absolute stereochemistry.



RN 501939-92-0 CAPLUS
CN 2-Oxazolidinone, 3-[4'-[4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl]-2-fluoro[1,1'-biphenyl]-4-yl]-5-[(3-isoxazolylamino)methyl]-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501939-96-4 CAPLUS
CN 2-Oxazolidinone, 3-[4'-[4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl]-2-fluoro[1,1'-biphenyl]-4-yl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 501940-44-9P, N-[(5S)-3-[2-Fluoro-4'-[5-(1H-1,2,3-triazol-1-yl)methyl)-4,5-dihydroisoxazol-3-yl]-1,1'-biphenyl-4-yl]-2-oxo-1,3-oxazolidin-5-yl)methyl]acetamide 501940-46-1P, (5R)-3-[4'-[5-(Hydroxymethyl)-4,5-dihydroisoxazol-3-yl]-1,1'-biphenyl-4-yl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 501940-48-3P, (5R)-3-[4'-[5-(Hydroxymethyl)-4,5-dihydroisoxazol-3-yl]-1,1'-biphenyl-4-yl]-5-(1H-1,2,3-triazol-1-yl)methyl)-1,3-oxazolidin-2-one 501940-50-7P, N-[(5S)-3-[2-Fluoro-4'-[5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl)-4,5-dihydroisoxazol-3-yl]-1,1'-biphenyl-4-yl]-2-oxo-1,3-oxazolidin-5-yl)methyl]acetamide 501940-54-1P, (5R)-3-[2-Fluoro-4'-[5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl)-4,5-

dihydroisoxazol-3-yl]-1,1'-biphenyl-4-yl]-5-(hydroxymethyl)-1,3-oxazolidin-2-one 501940-59-6P, (5R)-3-[2-Fluoro-4'-[5-(hydroxymethyl)-4,5-

dihydroisoxazol-3-yl]-1,1'-biphenyl-4-yl]-5-(1H-1,2,3-triazol-1-yl)methyl)-1,3-oxazolidin-2-one 501940-61-0P, N-[(5S)-3-[4'-[(5R)-5-(Hydroxymethyl)-4,5-dihydroisoxazol-3-yl]-1,1'-biphenyl-4-yl]-2-oxo-1,3-oxazolidin-5-yl)methyl]acetamide 501940-64-3P, N-[(5S)-3-[4'-[(5S)-5-(Hydroxymethyl)-4,5-dihydroisoxazol-3-yl]-1,1'-biphenyl-4-yl]-2-oxo-1,3-oxazolidin-5-yl)methyl]acetamide 501940-67-6P, (5S)-3-[2-Fluoro-4'-[5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl)-4,5-dihydroisoxazol-3-yl]-1,1'-biphenyl-4-yl]-5-[(isoxazol-3-ylamino)methyl]-1,3-oxazolidin-2-one 501940-72-3P, [3-[4'-[(5S)-5-(Acetylamino)methyl]-2-oxo-1,3-oxazolidin-3-yl]-1,1'-biphenyl-4-yl]-4,5-dihydroisoxazol-5-yl)methyl disodium phosphate 501940-90-5P, (5S)-3-[2,2'-Difluoro-4'-[5-(hydroxymethyl)-4,5-dihydroisoxazol-3-yl]-1,1'-biphenyl-4-yl]-5-[(isoxazol-3-ylamino)methyl]-1,3-oxazolidin-2-one


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; prepn. of oxazolidinones and/or isoxazolines as antibacterial agents)


RN 501939-85-1 CAPLUS

CN 2-Oxazolidinone, 5-[(acetyloxy)methyl]-3-[4'-[4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl]-2-fluoro[1,1'-biphenyl]-4-yl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501939-89-5 CAPLUS
CN Acetamide, N-[(5S)-3-[4'-[4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl][1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)



RN 501939-99-7 CAPLUS
CN Acetamide, N-[(5S)-3-[4'-[4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl]-2-fluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501940-01-8 CAPLUS
CN Acetamide, N-[(3-[2-fluoro-4'-[(5R)-5-(hydroxymethyl)-2-oxo-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-4,5-dihydro-5-isoxazolyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

CC(=O)N[C@@H]1C=NC=C1c1ccc(cc1F)-c2ccc(cc2)N3C(=O)O[C@H](R)C3


Absolute stereochemistry.



Absolute stereochemistry.


Cn1cncn1CN2C=CN=C2c3ccc(cc3-c4cc(F)cc(N5C(=O)OCC5)c4)c6cc(F)cc(N7C(=O)OCC7)c6

Absolute stereochemistry.



Absolute stereochemistry.


Absolute stereochemistry.




Absolute stereochemistry.

CC(C)(C)OC(=O)N1C[C@H](C2=CN=CC=C2)N1[C@@H](C3=CC=C(C=C3)C(F)=CC(F)=C3C4=CC=C(C=C4)C5=CN(C5)CO)C(=O)N1C[C@H](C2=CC=CC=C2)N1

Absolute stereochemistry.




Absolute stereochemistry.




RN 501940-41-6 CAPLUS
CN 2-Oxazolidinone, 3-[4'-[4,5-dihydro-5-(1H-1,2,3-triazol-1-ylmethyl)-3-isoxazolyl][1,1'-biphenyl]-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501940-42-7 CAPLUS
CN 2-Oxazolidinone, 3-[4'-[4,5-dihydro-5-(1H-1,2,3-triazol-1-ylmethyl)-3-isoxazolyl]-2-fluoro[1,1'-biphenyl]-4-yl]-5-[(4-methyl-1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501940-44-9 CAPLUS
CN Acetamide, N-[(5S)-3-[4'-[4,5-dihydro-5-(1H-1,2,3-triazol-1-ylmethyl)-3-isoxazolyl]-2-fluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinylmethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501940-46-1 CAPLUS
CN 2-Oxazolidinone, 3-[4'-[4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl][1,1'-biphenyl]-4-yl]-5-[(4-methyl-1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501940-48-3 CAPLUS
CN 2-Oxazolidinone, 3-[4'-[4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl][1,1'-biphenyl]-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501940-50-7 CAPLUS
CN Acetamide, N-[(5S)-3-[4'-[4,5-dihydro-5-[(4-methyl-1H-1,2,3-triazol-1-ylmethyl)-3-isoxazolyl]-2-fluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinylmethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501940-54-1 CAPLUS
CN 2-Oxazolidinone, 3-[4'-[4,5-dihydro-5-[(4-methyl-1H-1,2,3-triazol-1-ylmethyl)-3-isoxazolyl]-2-fluoro[1,1'-biphenyl]-4-yl]-5-(hydroxymethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501940-59-6 CAPLUS
CN 2-Oxazolidinone, 3-[4'-[4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl]-2-fluoro[1,1'-biphenyl]-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501940-19-8 CAPLUS
CN 2-Oxazolidinone,
3-[(4'-[5-[[[(1,1-dimethylethyl)dimethylsilyl]oxy)methyl]-
4,5-dihydro-3-isoxazolyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-5-[(4-methyl-
1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501940-20-1 CAPLUS
CN 2-Oxazolidinone,
3-[(4'-[5-[[[(1,1-dimethylethyl)dimethylsilyl]oxy)methyl]-
4,5-dihydro-3-isoxazolyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-5-[(1H-1,2,3-
triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501940-21-2 CAPLUS
CN Carbamic acid,
[(5R)-3-[4'-[5-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]met
hyl]-4,5-dihydro-3-isoxazolyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-
oxazolidinyl)methyl]-3-isoxazolyl-, 1,1-dimethylethyl ester (9CI) (CA
INDEX NAME)

Absolute stereochemistry.




RN 501940-22-3 CAPLUS
CN 2-Oxazolidinone,
3-[(4'-[5-[[[(1,1-dimethylethyl)dimethylsilyl]oxy)methyl]-
4,5-dihydro-3-isoxazolyl]-2'-fluoro[1,1'-biphenyl]-4-yl]-5-(hydroxymethyl)-
, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501940-23-4 CAPLUS
CN Acetamide,
N-[[[(5S)-3-[4'-[5-[[[(1,1-dimethylethyl)dimethylsilyl]oxy)methyl]-
4,5-dihydro-3-isoxazolyl]-2'-fluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-
oxazolidinyl)methyl]-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501940-56-3 CAPLUS
CN 2-Oxazolidinone, 3-[4'-[4,5-dihydro-5-[(4-methyl-1H-1,2,3-triazol-1-
yl)methyl]-3-isoxazolyl]-2-fluoro[1,1'-biphenyl]-4-yl]-5-[[[(1,1-
dimethylethyl)dimethylsilyl]oxy)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501940-62-1 CAPLUS
CN Acetamide,
N-[[[(5S)-3-[4'-[5-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]met
hyl]-4,5-dihydro-3-isoxazolyl]-1,1'-biphenyl]-4-yl]-2-oxo-5-
oxazolidinyl)methyl]-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501940-65-4 CAPLUS
CN Acetamide,
N-[[[(5S)-3-[4'-[5-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]met
hyl]-4,5-dihydro-3-isoxazolyl]-1,1'-biphenyl]-4-yl]-2-oxo-5-
oxazolidinyl)methyl]-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501940-68-7 CAPLUS
 CN Carbamic acid, [(5R)-3-(4'-[4,5-dihydro-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-3-isoxazolyl]-2-fluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-3-isoxazolyl-, 1,1-dimethylethyl ester [9CI] (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT



=> s 19

L13 1 L9

=> d ibib abs hitstr tot

L14 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)
ACCESSION NUMBER: 2006:342903 CAPLUS
DOCUMENT NUMBER: 144:390904
TITLE: Phenyl-substituted oxazolidinone derivatives and their preparation, pharmaceutical compositions, and use as antimicrobials
INVENTOR(S): Das, Biswajit; Ahmed, Shahadat; Yadav, Ajay Singh; Ghosh, Soma; Gujrati, Arti; Sharma, Pankaj; Rattan, Ashok
PATENT ASSIGNEE(S): Ranbaxy Laboratories Limited, India
SOURCE: PCT Int. Appl., 145 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO. KIND DATE APPLICATION NO. DATE
WO 2006038100 A1 20060413 WO 2004-1B2971 20051006
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, CA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
PRIORITY APPL. INFO.: US 2004-616964P P 20041008
GI



AB The invention relates to phenyl-substituted oxazolidinones I, or their pharmaceutically acceptable salts, solvates, esters, enantiomers,

L14 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)
CN Acetamide,
N-[[[(5S)-2-oxo-3-(2,3',6-trifluoro-4'-[(5S)-5-(hydroxymethyl)-2-oxo-3-oxazolidinyl]-1,1'-biphenyl)-4-yl]-5-oxazolidinyl)methyl]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L14 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)
diastereomers, N-oxides, polymorphs, prodrugs, or metabolites, as well as processes for their synthesis. In compds. I: A is pyridine-2,5-diyl, pyrimidine-2,5-diyl, furan-2,5-diyl, thiophene-2,5-diyl, and analogs; U and V are independently selected from H (both U and V cannot be H), lower alkyl, or halo; R is CH₂NORf, CH₂NOC(ORf), CH₂NOSORf, CH₂NOC(O)NHRf, heterocyclyl, or heteroaryl; Rf is H, alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, aryl, aralkyl, heteroaryl, heterocyclyl, heteroarylalkyl, or heterocyclylalkyl; R1 is azido, NCS, NHRf, NRf, NRf(Rf), NRf(Rf), NRf(Rf), NRf(Rf); Y is (C=O), (C=S), or SO₂; T is O, S, N(CN), N(MO₂), CH(MO₂); Rj is H, alkyl, alkenyl, cycloalkyl, aryl, aralkyl, heterocyclyl, heteroaryl, heteroarylalkyl, or heterocyclylalkyl; Rq is H, alkyl, cycloalkyl, aryl, aralkyl, heteroaryl, heterocyclyl, heteroarylalkyl or heterocyclylalkyl; Rs is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heteroarylalkyl or heterocyclylalkyl; with the proviso that:
when U is H, V is F, R is NHCOCH₃ and A is pyridine-2,5-diyl, then R is a 5-membered heteroaryl ring contg. two or four N atoms (wherein the 5-membered heteroaryl ring contg. four N atoms is linked through an N-atom to pyridine-2,5-diyl and is always substituted); when A is pyrimidine-2,5-diyl and U, V, and R1 are as defined above then R cannot be a 5-membered heterocyclyl ring contg. 2 hetero atoms. The invention also relates to pharmaceutical compns. contg. I as antimicrobials. I are useful antimicrobial agents (no data), effective against a no. of human and veterinary pathogens, including gram-pos. aerobic bacteria (for example, multiple-resistant staphylococci, streptococci, and enterococci), as well as anaerobic organisms (for example, Bacteroides spp. and Clostridia spp.), and acid fast organisms (for example, Mycobacterium tuberculosis, Mycobacterium avium and Mycobacterium spp.). Approx. 100 compds. I were prepd., and are claimed by name. The synthesis of most compds. I and a variety of intermediates is described. For instance, 5-bromopyridine-2-amine was (1) N-protected with BOC, followed by (2) conversion of the bromide to the boronic acid, (3) Pd-catalyzed coupling of the boronic acid with (S)-N-[[[(3-(4-iodo-3,5-difluorophenyl)-2-oxo-5-oxazolidinyl)methyl]acetamide, (4) N-deprotection with HCl, and (5) cyclization of the freed amine with 2,5-dimethoxytetrahydrofuran-3-carboxaldehyde, to give invention compd. II. I have good activity against multiply resistant Gram-pos. pathogens like methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococci (VRE), and Streptococcus pneumoniae. Some I have activity against multiple drug-resistant tuberculosis (MDR-TB) strain, while others have significant activity against important anaerobic bacteria. I are also active against MAI sirens and Gram-neg. pathogens like Moraxella catarrhalis and Haemophilus influenzae.
IT 88329-96-7P, N-[[[(5S)-2-oxo-3-(2,3',6-trifluoro-4'-[(5S)-5-(hydroxymethyl)-2-oxo-1,3-oxazolidin-3-yl]biphenyl-4-yl]-1,3-oxazolidin-5-yl)methyl]acetamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of phenyl-substituted oxazolidinone derivs. as antimicrobials)
RN 88329-96-7 CAPLUS

L14 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 2004:588234 CAPLUS
DOCUMENT NUMBER: 141:140417
TITLE: Preparation of novel biphenyls, their intermediates, and their use as bactericides
INVENTOR(S): Shikawa, Seiji; Ishikawa, Makoto; Yanagisawa, Yumiko; Kawaguchi, Masami; Fujita, Toshiki; Maghashi, Kazunori; Toshiaki, Masami; Meiji Seika Kaisha, Ltd.; Japan
PATENT ASSIGNEE(S): Jpn. Kokai Tokkyo Koho, 185 pp.
SOURCE: CODEN: JKKXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:
PATENT NO. KIND DATE APPLICATION NO. DATE
JP 2004203809 A2 20040722 JP 2002-376218 20021226
PRIORITY APPL. INFO.: JP 2002-376218 20021226
OTHER SOURCE(S): MARPAT 141:140417
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT
AB Title compds. I (R1-R8 = H, halo, NH₂, glycyamino, (un)substituted alkoxy; T, Q = halo, OH, (un)substituted Cl-8 alkoxy, (un)substituted Cl-8
C1-8 alkanoyloxy, NH₂, N3, (un)substituted unsatd. heterocyclyl, etc.), useful for controlling (drug-resistant) bacteria, are prepared by conversion of 3-(substituted phenyl)-2-oxooxazolidines II (R1-R4, Q = same as above; X = iodine, Br, Cl, haloalkylsulfonyloxy, diaryl phosphate residue) into 3-(boron-substituted phenyl)-2-oxooxazolidines II (R1-R4, Q = same as above; X = BR₉R₁₀; R₉, R₁₀ = OH, Cl-8 linear alkyl(oxy), C3-8 branched alkyl(oxy); R₉R₁₀ may be linked), then coupling with oxazolidinylbenzenes III (R5-R8, T = same as above; Y = iodine, Br, Cl, haloalkylsulfonyloxy, diaryl phosphate residue). Thus, coupling of
3-(2-fluoro-4-iodophenyl)-2-oxo-5(R)-phthalimidomethylloxazolidine with 5(S)-acetamidomethyl-3-(3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-2-oxooxazolidine in the presence of K phosphate and tetrakis(triphenylphosphine)palladium in DMF gave the corresponding biphenyl compound with 66% yield, which showed MIC of 2 µg/mL against methicillin-resistant Staphylococcus aureus.
IT 501939-75-9P 627541-97-3P 627542-07-8P
627542-15-8P 627542-17-0P 627542-22-7P
627542-26-1P 627542-28-3P 627542-37-4P
627542-40-9P 627542-42-1P 627542-45-4P
627542-48-7P 627542-52-3P 627542-60-3P
627542-66-9P 627542-70-5P 627542-72-7P
627542-80-7P 627542-81-8P 627542-82-9P
627542-84-1P 627542-85-2P 627542-87-4P
627542-88-5P 627542-89-6P 627542-95-4P
627542-96-5P 627542-97-6P 627542-98-3P
627542-98-5P 627542-99-6P 627542-99-7P
627542-99-8P 627542-99-9P 627542-99-9P

New 2004/07/12

Not a art

later than FD

11/24/2003

L14 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


724793-10-6P 724793-19-5P 724793-21-9P
724793-24-2P 724793-27-5P 724793-30-0P
724793-33-3P 724793-36-6P 724793-39-9P
724793-42-4P 724793-48-0P 724793-50-4P
724793-61-7P 724793-66-2P 724793-69-5P
724793-75-3P

RI: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of (oxoxazolidinyl)biphenyls as bactericides for (drug-resistant) bacteria)

RN 501939-75-9 CAPLUS

CN Acetamide, N,N'-[(2,2'-difluoro[1,1'-biphenyl]-4,4'-diyl)bis[(5S)-2-oxo-3,5-oxazolidinediyl)methylene]]bis- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 627541-97-3 CAPLUS

CN Acetamide,

N-[[[(5S)-3-[4'-[(5S)-5-(aminomethyl)-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 627542-07-8 CAPLUS

CN 11-Oxa-2,4,9-triazatridec-2-enoic acid, 8-[[[(5S)-3-[4'-[(5S)-5-

[(acetylaminomethyl)-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]amino]carbonyl]-3-[[[(1,1-

L14 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B

NHAc

RN 627542-17-0 CAPLUS


CN Acetamide, N-[[[(5S)-3-[4'-[(5S)-5-(acetylaminomethyl)-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-2-amino-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 627542-16-9

CMF C24 H25 F2 N5 O6

Absolute stereochemistry.




CM 2

L14 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


dimethylethoxy)carbonyl]amino]-12,12-dimethyl-10-oxo-, 1,1-dimethylethyl ester, (8S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 627542-15-8 CAPLUS

CN Carbamic acid, [2-[[[(5S)-3-[4'-[(5S)-5-(acetylaminomethyl)-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]amino]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L14 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CRN 76-05-1
CMF C2 H F3 O2




RN 627542-22-7 CAPLUS

CN Carbamic acid, [1-[[[(5S)-3-[4'-[(5S)-5-(acetylaminomethyl)-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]amino]carbonyl]-1,2-ethanediy]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

NHAc

RN 627542-26-1 CAPLUS


CN Propanoic acid, 3-[[[(5S)-3-[4'-[(5S)-5-(acetylaminomethyl)-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]amino]-3-oxo-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 627542-28-3 CAPLUS
 CN Carbamic acid, [(2,2'-difluoro[1,1'-biphenyl]-4,4'-diyl)bis[(5S)-2-oxo-3,5-oxazolidinediyl)methylene]]bis-, bis(1,1-dimethylethyl) ester (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.



RN 627542-37-4 CAPLUS
 CN Carbamic acid, [(2,2'-difluoro[1,1'-biphenyl]-4,4'-diyl)bis[(5S)-2-oxo-3,5-oxazolidinediyl)methyleneimino(2-oxo-2,1-ethanediyl)]]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



RN 627542-40-9 CAPLUS
 CN Acetamide, N,N'-[(2,2'-difluoro[1,1'-biphenyl]-4,4'-diyl)bis[(5S)-2-oxo-3,5-oxazolidinediyl)methylene]]bis[2-amino-, mono(trifluoroacetate) (9CI)
 (CA INDEX NAME)


CM 1

CRN 627542-39-6


CMF C24 H26 F2 N6 O6

Absolute stereochemistry.

PAGE 1-B



PAGE 1-A



PAGE 1-B

NH₂

CM 2

CRN 76-05-1


CMF C2 H F3 O2




RN 627542-42-1 CAPLUS
 CN Carbamic acid, [(5S)-3-[4'-[(5S)-5-[[[(1,1-dimethylethoxy)carbonyl]amino]acetyl]amino]methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 627542-45-4 CAPLUS
 CN Acetamide, 2-amino-N-[[[(5S)-3-[4'-[(5S)-5-(aminomethyl)-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 627542-44-3

CMF C22 H23 F2 N5 O5

Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 627542-48-7 CAPLUS


CM 2-Oxazolidinone, 3-[2,2'-difluoro-4'-[(5R)-5-(methoxymethyl)-2-oxo-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-5-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 627542-52-3 CAPLUS

CM Carbamic acid, 3-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-, (5R)- (9CI) (CA INDEX NAME)



RN 627542-70-5 CAPLUS


CM 2-Oxazolidinone, 3,3'-[2,2'-difluoro[1,1'-biphenyl]-4,4'-diyl]bis[5-(methoxymethyl)-2-oxo-3-oxazolidinyl]-, (5S,5'S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 627542-69-2

CMF C22 H24 F2 N4 O4

Absolute stereochemistry.




CM 2

CRN 76-05-1

CMF C2 H F3 O2

y]methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 627542-60-3 CAPLUS

CM Carbamic acid, 3-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 627542-66-9 CAPLUS

CM Carbamic acid, 3-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 627542-72-7 CAPLUS

CM Propanoic acid, 3-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A


PAGE 1-B

t-BuO-t

RN 627542-80-7 CAPLUS


CM Butanoic acid, 3-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 627542-81-8 CAPLUS
CN 2-Oxazolidinone, 3,3'-(2,2'-dimethoxy[1,1'-biphenyl]-4,4'-diyl)bis[5-(hydroxymethyl)-, (5R,5'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 627542-82-9 CAPLUS
CN 2-Oxazolidinone, 3,3'-(2,2'-dimethoxy[1,1'-biphenyl]-4,4'-diyl)bis[5-[(methylsulfonyl)oxy]methyl]-, (5R,5'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 627542-84-1 CAPLUS
CN 2-Oxazolidinone, 3,3'-(2,2'-dimethoxy[1,1'-biphenyl]-4,4'-diyl)bis[5-(azidomethyl)-, (5R,5'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 627542-85-2 CAPLUS
CN 2-Oxazolidinone, 3,3'-(2,2'-dimethoxy[1,1'-biphenyl]-4,4'-diyl)bis[5-(aminomethyl)-, (5S,5'S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 627542-87-4 CAPLUS
CN 2-Oxazolidinone, 5-(azidomethyl)-3-[4'-[(5R)-5-(hydroxymethyl)-2-oxo-3-oxazolidinyl]-2,2'-dimethoxy[1,1'-biphenyl]-4-yl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 627542-88-5 CAPLUS
CN 2-Oxazolidinone, 5-(azidomethyl)-3-[4'-[(5R)-5-(hydroxymethyl)-2-oxo-3-oxazolidinyl]-2,2'-dimethoxy[1,1'-biphenyl]-4-yl]-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 627542-89-6 CAPLUS
CN Acetamide, N-[(5S)-3-[4'-[(5R)-5-(acetoxy)methyl]-2-oxo-3-oxazolidinyl]-2,2'-dimethoxy[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinylmethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 627542-95-4 CAPLUS
CN 1H-Indole-1,3(2H)-dione, 2-[(5S)-3-[2,2'-difluoro-4'-[(5R)-5-(methoxymethoxy)methyl]-2-oxo-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinylmethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

OMe


RN 627542-96-5 CAPLUS
 CN 2-Oxazolidinone, 5-(aminomethyl)-3-[2,2'-difluoro-4'-[(5R)-5-(methoxymethoxy)methyl]-2-oxo-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 627542-97-6 CAPLUS
 CN Acetamide, N-[[[(5S)-3-[2,2'-difluoro-4'-[(5R)-5-(methoxymethoxy)methyl]-2-oxo-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 724792-91-0 CAPLUS
 CN 1H-Isindole-1,3(2H)-dione, 2,2'-[(2-fluoro[1,1'-biphenyl]-4,4'-diyl)bis[(5S)-2-oxo-3,5-oxazolidinediyl]methylene]bis- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 724792-92-1 CAPLUS
 CN 2-Oxazolidinone, 3,3'-(2-fluoro[1,1'-biphenyl]-4,4'-diyl)bis[5-(aminomethyl)-, (5S,5'S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 724792-86-3 CAPLUS
 CN Acetamide, N-[[[(5S)-3-[4'-[(5S)-5-[(1,3-dihydro-1,3-dioxo-2H-isindol-2-yl)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 724792-88-5 CAPLUS
 CN Acetamide, N-[[[(5S)-3-[4'-[(5R)-5-(acetyloxy)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 724792-95-4 CAPLUS
 CN Carbamic acid, [[[(5R)-3-[4'-[(5S)-5-(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]methyl]-3-isoxazolyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 724792-97-6 CAPLUS
 CN Carbamic acid, [[[(5R)-3-[4'-[(5S)-5-(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]methyl]-1,2,5-thiadiazol-3-yl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724793-05-9 CAPLUS
CN Acetamide, N-[[{[5S]-3-{4'-[5R]-5-{[2,3-dihydroxypropoxy)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN	724793-10-6	CAPLUS
CN	Carbamic acid, [[(5R)-3-[4'-(5S)-5-[[[[[1,1-dimethylethoxy]carbonyl]amino]acetyl]amino]methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]methyl]-3-isoxazolyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)	

Absolute stereochemistry.

PAGE 1-A




PAGE 1-8



RN	724793-19-5	CAPLUS
CN	Carbamic acid, [1-[[[5R]-3-[4'-[[5S]-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro{1,1'-biphenyl}-4-yl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)	

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

$$-\text{NHAc}$$


```

RN      724793-21-9  CAPLUS
CN      Acetamide,
N-[[[(5S)-3-[4'-[ (5R)-5-[[2-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-
yl)ethoxy]methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-
2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

```

Absolute stereochemistry.

PAGE 1-A




PAGE 1-8

NHAc

RN 724793-24-2 CAPLUS
 CN Carbamic acid,
 [2-[[[(5S)-3-{2,2'-difluoro-4'-[[[(5R)-2-oxo-5-(2H-tetrazol-2-yl)methyl]-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]methylamino]-2-oxoethyl]-, 1,1-dimethylethyl ester (SCI)
 (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

— OBU-t

RN 724793-27-5 CAPLUS
 CN Carbamic acid,
 [2-[[[(5S)-3-[2,2'-difluoro-4'-[(5R)-2-oxo-5-(1H-tetrazol-1-yl)methyl]-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]amino]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI)

Absolute stereochemistry.




PAGE 1-B


OBu-t

RN 724793-30-0 CAPLUS
CN Carbamic acid, [2-[[[[(5S)-3-[4'-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]amino]carbonyl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A



PAGE 1-B




RN 724793-39-9 CAPLUS
CN Carbamic acid, [(5R)-3-[4'-[(5S)-5-[[[[(1,1-dimethylethoxy)carbonyl]amino]acetyl]amino]methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinylmethyl]-1,2,5-thiadiazol-3-yl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

NHAc

RN 724793-33-3 CAPLUS
CN Carbamic acid, [(5S)-3-[4'-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinylmethyl][2-[[[(1,1-dimethylethoxy)carbonyl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B

NHAc

RN 724793-36-6 CAPLUS
CN Carbamic acid, [2-[[[[(5S)-3-[2,2'-difluoro-4'-[(5R)-2-oxo-5-[(1,2,5-thiadiazol-3-yloxy)methyl]-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinylmethyl]amino]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 724793-42-4 CAPLUS
CN Carbamic acid, [(5S)-3-[4'-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinylmethyl][2-[[[(1,1-dimethylethoxy)carbonyl]amino]-5-thiazolyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B


t-Bu-

RN 724793-48-0 CAPLUS
CN 4-Morpholinecarboxylic acid, 2-[[[(5S)-3-{4'-[(5S)-5-


[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinylmethylamino]carbonyl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 724793-61-7 CAPLUS
CN Carbamic acid, [5-[[[(5S)-3-{4'-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinylmethylamino]carbonyl]-1,3-phenylene]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 724793-50-4 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[2-[[[(5S)-3-{4'-[(5S)-5-

[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinylmethylamino]carbonyl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 724793-66-2 CAPLUS
CN Carbamic acid, [(1R)-2-[[[(5S)-3-{4'-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinylmethylamino]carbonyl]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 724793-69-5 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[[[(5S)-3-{4'-[(5S)-5-

[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinylmethylamino]carbonyl]-, 1,1-dimethylethyl ester, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L14 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



RN 724793-75-3 CAPLUS
CN Acetamide,
N,N'-bis-[(5-amino-2,2'-difluoro[1,1'-biphenyl]-4,4'-diyl)bis[(5S)-2-oxo-3,5-oxazolidinediyl)methylene]]bis- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 501939-79-3P 627541-96-2P 627541-98-4P
627541-99-5P 627542-01-2P 627542-02-3P
627542-04-5P 627542-06-7P 627542-10-3P
627542-11-4P 627542-12-5P 627542-14-7P
627542-18-1P 627542-19-2P 627542-20-5P
627542-24-9P 627542-25-0P 627542-27-2P
627542-32-9P 627542-36-3P 627542-46-5P
627542-50-1P 627542-55-6P 627542-57-8P
627542-64-7P 627542-71-6P 627542-74-9P
627542-75-0P 627542-76-1P 627542-77-2P
627542-78-3P 627542-79-4P 627542-83-0P
627542-86-3P 627542-90-9P 627542-98-7P
627543-00-4P 627543-01-5P 627543-02-6P
724792-87-4P 724792-89-6P 724792-93-2P
724792-94-3P 724792-96-5P 724792-98-7P
724793-04-0P 724793-06-0P 724793-07-1P
724793-09-3P 724793-12-8P 724793-13-9P
724793-15-1P 724793-16-2P 724793-18-4P
724793-20-8P 724793-22-0P 724793-23-1P
724793-26-4P 724793-29-7P 724793-32-2P


L14 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)
CN Acetamide, N-[[[(5S)-3-[2,2'-difluoro-4'-[(5S)-2-oxo-5-[(1-thioxoethyl)amino)methyl]-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 627541-99-5 CAPLUS
CN Carbamic acid,
[(1S)-2-[[[(5S)-3-[4'-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]amino]-1-[(1,1-dimethylethoxy)methyl]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 627542-01-2 CAPLUS
CN Propanamide, N-[[[(5S)-3-[4'-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-2-amino-3-hydroxy-, (2S)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CH 1

CRN 627542-00-1
CMF C25 H27 F2 N5 O7

L14 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)


724793-35-5P 724793-38-8P 724793-41-3P
724793-43-5P 724793-47-9P 724793-49-1P
724793-51-5P 724793-53-7P 724793-55-9P
724793-57-1P 724793-58-2P 724793-59-3P
724793-60-6P 724793-63-9P 724793-65-1P
724793-68-4P 724793-71-9P 724793-73-1P
724793-74-2P 724793-77-5P 724793-78-6P
724793-79-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of (oxoxazolidinyl)biphenyls as bactericides for (drug-resistant) bacteria)


RN 501939-79-3 CAPLUS
CN 2-Oxazolidinone, 3,3'-(2,2'-difluoro[1,1'-biphenyl]-4,4'-diyl)bis[5-(hydroxymethyl)-, (5R,5'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 627541-96-2 CAPLUS
CN Carbamic acid, [[[(5S)-3-[4'-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 627541-98-4 CAPLUS

L14 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)

Absolute stereochemistry.




CH 2

CRN 76-05-1
CMF C2 H F3 O2



RN 627542-02-3 CAPLUS
CN Acetamide,
N-[[[(5S)-3-[4'-[(5S)-5-[(aminoiminomethyl)amino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L14 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 627542-04-5 CAPLUS
 CN 1H-Imidazole-1-carboxylic acid, 5-[(2S)-3-[[[(5S)-3-(4'-[(5S)-5-

[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinylmethylamino]-2-[[[(1,1-dimethylethoxy)carbonyl]amino]-3-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A



PAGE 1-B

RN 627542-06-7 CAPLUS
 CN 1H-Imidazole-4-propanamide, N-[[[(5S)-3-[4'-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinylmethyl]-α-amino-, (αS)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 627542-05-6
 CMF C28 H29 F2 N7 O6

Absolute stereochemistry.

L14 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B

NHAc

CM 2

CRN 76-05-1
 CMF C2 H F3 O2



RN 627542-10-3 CAPLUS
 CN Pentanamide, N-[[[(5S)-3-[4'-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinylmethyl]-2-amino-5-[(aminoiminomethyl)amino]-, (2S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 627542-09-0
 CMF C28 H34 F2 N8 O6

Absolute stereochemistry.

L14 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B

NHAc

CM 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 627542-11-4 CAPLUS
 CN D-Glucopyranuronamide, N-[[[(5S)-3-[4'-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinylmethyl]-, 1,2,3,4-tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L14 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 627542-12-5 CAPLUS
 CN Carbamic acid, [[[(5S)-3-[4'-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinylmethylamino]-3-hydroxy-4-oxobutyl]-, (4-methoxyphenyl)methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A






RN 627542-14-7 CAPLUS
CN Butanamide, N-[(5S)-3-[4'-[(5S)-5-{(acetylamino)methyl}-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinylmethyl]-4-amino-2-hydroxy-, (2S)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CH 1

CRN 627542-13-6
CMF C26 H29 F2 N5 O7

Absolute stereochemistry.




CH 2

CRN 76-05-1
CMF C2 H F3 O2



RN 627542-18-1 CAPLUS
CN Acetamide, N-[(5S)-3-[4'-[(5S)-5-{(acetylamino)methyl}-2-oxo-3-




RN 627542-24-9 CAPLUS
CN Propanamide, N-[(5S)-3-[4'-[(5S)-5-{(acetylamino)methyl}-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinylmethyl]-2,3-diamino-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 627542-23-8
CMF C25 H28 F2 N6 O6


Absolute stereochemistry.



CH 2


CRN 76-05-1
CMF C2 H F3 O2

Absolute stereochemistry.



RN 627542-19-2 CAPLUS
CN 1-Cyclohexene-1-carboxamide, N-[(5S)-3-[4'-[(5S)-5-{(acetylamino)methyl}-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinylmethyl]-3,4,5-trihydroxy-, (3R,4S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 627542-20-5 CAPLUS
CN Propanamide, N-[(5S)-3-[4'-[(5S)-5-{(acetylamino)methyl}-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinylmethyl]-2,3-dihydroxy-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 627542-25-0 CAPLUS
CN 2-Oxazolidinone, 5-[(acetyloxy)methyl]-3-[2,2'-difluoro-4'-[(5R)-5-(hydroxymethyl)-2-oxo-3-oxazolidinyl]-1,1'-biphenyl]-4-yl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 627542-27-2 CAPLUS
CN Propanoic acid, 3-[[[(5S)-3-[4'-[(5S)-5-{(acetylamino)methyl}-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinylmethyl]amino]-3-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 627542-32-9 CAPLUS
CN 2-Oxazolidinone, 3,3'-(2,2'-difluoro[1,1'-biphenyl]-4,4'-diyl)bis[5-(aminomethyl)-, (5S,5'S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

L14 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CRN 627542-31-8
CMF C20 H20 F2 N4 O4

Absolute stereochemistry.




CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 627542-36-3 CAPLUS
CN 2-Oxazolidinone, 3,3'-(2,2'-difluoro[1,1'-biphenyl]-4,4'-diyl)bis[5-(methoxymethyl)-, (5R,5'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 627542-46-5 CAPLUS
CN Acetamide, N-[[[(5S)-3-[4'-[(5S)-5-[(dimethylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinylmethyl]-, (5R,5'R)- (9CI) (CA INDEX NAME)

L14 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




CM 2
CRN 76-05-1
CMF C2 H F3 O2



RN 627542-57-8 CAPLUS
CN 2-Oxazolidinone, 3,3'-(2,2'-difluoro[1,1'-biphenyl]-4,4'-diyl)bis[5-[(dimethylamino)methyl]-, (5S,5'S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 627542-64-7 CAPLUS
CN 2-Oxazolidinone, 5-(aminomethyl)-3-[4'-[(5S)-5-[(dimethylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinylmethyl]-, (5S,5'S)- (9CI) (CA INDEX NAME)
CM 1
CRN 627542-63-6
CMF C22 H24 F2 N4 O4


L14 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Absolute stereochemistry.



RN 627542-50-1 CAPLUS
CN 2-Oxazolidinone, 3-[2,2'-difluoro-4'-[(5R)-5-(hydroxymethyl)-2-oxo-3-oxazolidinyl]-1,1'-biphenyl]-4-yl]-5-(methoxymethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 627542-55-6 CAPLUS
CN 2-Oxazolidinone, 5-(aminomethyl)-3-[2,2'-difluoro-4'-[(5R)-5-(hydroxymethyl)-2-oxo-3-oxazolidinyl]-1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinylmethyl]-, (5R)- (9CI) (CA INDEX NAME)

CM 1
CRN 627542-54-5
CMF C20 H19 F2 N3 O5

Absolute stereochemistry.

L14 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Absolute stereochemistry.




CM 2
CRN 76-05-1
CMF C2 H F3 O2



RN 627542-71-6 CAPLUS
CN Acetamide, N,N'-[(2,2'-difluoro[1,1'-biphenyl]-4,4'-diyl)bis[5-(aminomethyl)-2-oxo-3-oxazolidinylmethyl]-, (5R,5'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 627542-74-9 CAPLUS
CN Propanoic acid, 3-[[[(5S)-3-[4'-[(5S)-5-(aminomethyl)-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinylmethyl]amino]-3-oxo-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 627542-73-8
CMF C23 H22 F2 N4 O7

Absolute stereochemistry.



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 627542-75-0 CAPLUS
CN Acetamide, N,N'-[(2,2'-difluoro[1,1'-biphenyl]-4,4'-diyl)bis[(5S)-2-oxo-3,5-oxazolidinediyl)methylene]]bis[2-(acetylamino)- (9CI) (CA INDEX NAME)]

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

NHAC


RN 627542-76-1 CAPLUS
CN Acetamide, N-[(5S)-3-[4'-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)]

Absolute stereochemistry.



RN 627542-77-2 CAPLUS
CN Acetamide, N,N'-[(2,2'-difluoro[1,1'-biphenyl]-4,4'-diyl)bis[(5S)-2-oxo-3,5-oxazolidinediyl)methylene]]bis[2-(dimethylamino)- (9CI) (CA INDEX NAME)]

Absolute stereochemistry.




PAGE 1-B

NMe2

RN 627542-78-3 CAPLUS
CN Acetamide, N-[(5S)-3-[4'-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-2-(dimethylamino)- (9CI) (CA INDEX NAME)]


Absolute stereochemistry.



RN 627542-79-4 CAPLUS
CN Acetamide, N-[(5S)-3-[2,2'-difluoro-4'-[(5S)-5-(1H-imidazol-1-ylmethyl)-2-oxo-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-


(9CI) (CA INDEX NAME)]

Absolute stereochemistry.



RN 627542-83-0 CAPLUS
CN 2-Oxazolidinone, 3-[2,2'-dimethoxy-4'-[(5R)-5-[(methylsulfonyl)oxy]methyl]-2-oxo-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-5-(hydroxymethyl)-, (5R)- (9CI) (CA INDEX NAME)]


Absolute stereochemistry.



RN 627542-86-3 CAPLUS
CN Acetamide, N,N'-[(2,2'-dimethoxy[1,1'-biphenyl]-4,4'-diyl)bis[(5S)-2-oxo-3,5-oxazolidinediyl)methylene]]bis- (9CI) (CA INDEX NAME)]


Absolute stereochemistry.

L14 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 627542-90-9 CAPLUS
CN Acetamide, N-[(5S)-3-[(4'-(5R)-5-(hydroxymethyl)-2-oxo-3-oxazolidinyl)-2,2'-dimethoxy[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 627542-98-7 CAPLUS
CN Acetamide, N-[(5S)-3-[(2,2'-difluoro-4'-(5R)-5-(hydroxymethyl)-2-oxo-3-oxazolidinyl)[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




L14 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 724792-87-4 CAPLUS
CN 1H-Imidazole-2-carboxamide, N-[(5S)-3-[(4'-(5S)-5-(acetylamino)methyl)-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 724792-89-6 CAPLUS
CN Acetamide, N-[(5S)-3-[(2,2'-difluoro-4'-(5R)-5-[[[methylsulfonyl]amino]methyl]-2-oxo-3-oxazolidinyl)[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

L14 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 627543-00-4 CAPLUS
CN Acetamide, N-[(5S)-3-[(4'-(5S)-5-(acetylamino)methyl)-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-2-[(aminoiminomethyl)amino]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 627543-01-5 CAPLUS
CN Acetamide, N-[(5S)-3-[(2,2'-difluoro-4'-(5R)-5-(3-isoxazolyloxy)methyl)-2-oxo-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 627543-02-6 CAPLUS
CN Acetamide, N-[(5S)-3-[(2,2'-difluoro-4'-(5R)-2-oxo-5-[(1,2,5-thiadiazol-3-yl)oxy]methyl)-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.

L14 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 724792-93-2 CAPLUS
CN Acetamide, N,N'-[(2-fluoro[1,1'-biphenyl]-4,4'-diyl)bis[[[(5S)-2-oxo-3,5-oxazolidinediyl]methylene]]bis- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 724792-94-3 CAPLUS
CN Acetamide, N-[(5S)-3-[(2,2'-difluoro-4'-(5R)-2-oxo-5-[(1H-1,2,3-triazol-1-yl)methyl]-3-oxazolidinyl)[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 724792-96-5 CAPLUS
 CN Acetamide, N-[(5S)-3-[2,2'-difluoro-4'-[(5S)-5-[(3-isoxazolylamino)methyl]-2-oxo-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724792-98-7 CAPLUS
 CN Acetamide,
 N-[(5S)-3-[2,2'-difluoro-4'-[(5S)-2-oxo-5-[(1,2,5-thiadiazol-3-ylamino)methyl]-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 724793-07-1 CAPLUS
 CN Carbamic acid, [(5S)-3-[4'-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-, 2-[(1,1-dimethylethoxy)carbonyl]amino]ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




RN 724793-09-3 CAPLUS
 CN Carbamic acid, [(5S)-3-[4'-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-, 2-aminoethyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 724793-08-2
 CMF C25 H27 F2 N5 O7

PAGE 1-B




RN 724793-04-8 CAPLUS
 CN Carbamic acid, [(5S)-3-[4'-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724793-06-0 CAPLUS
 CN Acetamide,
 N-[(5S)-3-[2,2'-difluoro-4'-[(5R)-5-[(2-hydroxyethoxy)methyl]-2-oxo-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 724793-12-8 CAPLUS
 CN Acetamide, 2-amino-N-[(5S)-3-[2,2'-difluoro-4'-[(5S)-5-[(3-isoxazolylamino)methyl]-2-oxo-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 724793-11-7
 CMF C25 H24 F2 N6 O6

Absolute stereochemistry.




CM 2

CRN 76-05-1
CMF C2 H F3 O2


RN 724793-13-9 CAPLUS
CN Carbamic acid, [2-[[[(5S)-3-[2,2'-difluoro-4'-{[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]methyl]amino]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)]

Absolute stereochemistry.


PAGE 1-A



PAGE 1-A



PAGE 1-B



RN 724793-18-4 CAPLUS
CN Acetamide, 2-amino-N-[[[(5S)-3-[2,2'-difluoro-4'-{[(5R)-5-[(3-isoxazolyloxy)methyl]-2-oxo-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)]

CM 1

CRN 724793-17-3
CMF C25 H23 F2 N5 O7

Absolute stereochemistry.

PAGE 1-B


-OBu-t

RN 724793-15-1 CAPLUS
CN Acetamide, 2-amino-N-[[[(5S)-3-[2,2'-difluoro-4'-{[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)]

CM 1

CRN 724793-14-0
CMF C24 H23 F2 N7 O5

Absolute stereochemistry.




CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 724793-16-2 CAPLUS
CN Carbamic acid, [2-[[[(5S)-3-[2,2'-difluoro-4'-{[(5R)-5-[(3-isoxazolyloxy)methyl]-2-oxo-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]methyl]amino]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)]

Absolute stereochemistry.




CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 724793-20-8 CAPLUS
CN Acetamide, N-[[[(5S)-3-[4'-{[(5R)-5-[[5-(aminomethyl)-1H-1,2,3-triazol-1-yl]methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)]


Absolute stereochemistry.



RN 724793-22-0 CAPLUS


L14 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN Acetamide, N-[(5S)-3-[4'-[(5R)-5-[(2-aminoethoxy)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724793-23-1 CAPLUS
 CN Acetamide, N-[(5S)-3-[2,2'-difluoro-4'-[(5S)-2-oxo-5-[[[(3-pyridinylamino)thioxomethyl]amino)methyl]-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 724793-26-4 CAPLUS
 CN Acetamide, 2-amino-N-[(5S)-3-[2,2'-difluoro-4'-[(5R)-2-oxo-5-(2H-tetrazol-2-ylmethyl)-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 724793-25-3
 CMF C23 H22 F2 N8 O5

Absolute stereochemistry.

L14 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 724793-32-2 CAPLUS
 CN Acetamide, N-[(5S)-3-[4'-[(5S)-5-[[[(2-aminoethyl)amino]carbonyl]amino]methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 724793-31-1
 CMF C25 H28 F2 N6 O6

Absolute stereochemistry.

L14 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 724793-29-7 CAPLUS
 CN Acetamide, 2-amino-N-[(5S)-3-[2,2'-difluoro-4'-[(5R)-2-oxo-5-(1H-tetrazol-1-ylmethyl)-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 724793-28-6
 CMF C23 H22 F2 N8 O5

Absolute stereochemistry.

L14 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 724793-35-5 CAPLUS
 CN Acetamide, N-[(5S)-3-[4'-[(5S)-5-[[[(2-aminoethyl)amino]methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 724793-34-4
 CMF C24 H27 F2 N5 O5

Absolute stereochemistry.



L14 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 724793-38-8 CAPLUS
CN Acetamide, 2-amino-N-[[[(5S)-3-[2,2'-difluoro-4'-[(5R)-2-oxo-5-[(1,2,5-thiadiazol-3-yloxy)methyl]-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 724793-37-7
CMF C24 H22 F2 N6 O6 S

Absolute stereochemistry.




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 724793-41-3 CAPLUS
CN Acetamide, 2-amino-N-[[[(5S)-3-[2,2'-difluoro-4'-[(5S)-2-oxo-5-[(1,2,5-

L14 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 724793-47-9 CAPLUS
CN 4-Piperidinecarboxamide, N-[[[(5S)-3-[4'-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 724793-46-8
CMF C28 H31 F2 N5 O6

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 724793-49-1 CAPLUS


L14 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

thiadiazol-3-ylamino)methyl]-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 724793-40-2
CMF C24 H23 F2 N7 O5 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 724793-43-5 CAPLUS
CN Acetamide, N-[[[(5S)-3-[4'-[(5S)-5-[[[(2-amino-5-thiazolyl)methyl]amino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L14 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


CN 2-Morpholinecarboxamide, N-[[[(5S)-3-[4'-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724793-51-5 CAPLUS
CN 1-Piperazineacetamide, N-[[[(5S)-3-[4'-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 724793-53-7 CAPLUS
CN Acetamide, N-[[[(5S)-3-[4'-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-2-(methylamino)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 724793-52-6
CMF C25 H27 F2 N5 O6

Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 02



RN	724793-55-9	CAPLUS
CN	2-Pyrrolidinecarboxamide, N-[[{(5S)-3-{4'-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-, (2S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)	


CM 1
CRN 724793-54-8
CMF C27 H29 F2 N5 O6

Absolute stereochemistry.





RN 724793-58-2 CAPLUS
CN Pyrazinecarboxamide,
N-[[(5S)-3-{4'-[(5S)-5-{(acetylamino)methyl}-2-oxo-3-
oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-
oxazolidinylmethyl}- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724793-59-3 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[(5S)-3-{4'-[(5S)-5-{[acetylamino]methyl}-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl}-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



CM 2

CRN 76-05-1



CMF C2 H F3 02



RN 724793-57-1 CAPLUS
CN 2-Piperazinecarboxamide, N-[[(5S)-3-[4'-[(5S)-5-[acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1
CRN 724793-56-0
CMF C27 H30 F2 N6 O6


Absolute stereochemistry.



RN 724793-63-9 CAPLUS
CN Benzamide, N-[[{5S)-3-[4'-{5S)-5-{(acetylamino)methyl}-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinylmethyl]-3,5-diamino-, mono(trifluoroacetate) (9CI) (CA
INDEX
NAME)

CM 1
CRN 724793-62-8
CMF C29 H28 F2 N6 O6

Absolute stereochemistry.



CM 2

CRN 76-05-1

L14 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CMF C2 H F3 O2




RN 724793-65-1 CAPLUS
CN Propanamide, N-[[[(5S)-3-{4'-[(5S)-5-{(acetylamino)methyl}-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-3-amino-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 724793-64-0
CMF C25 H27 F2 N5 O6

Absolute stereochemistry.




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 724793-68-4 CAPLUS
CN Propanamide, N-[[[(5S)-3-{4'-[(5S)-5-{(acetylamino)methyl}-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-2-amino-, (2R)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)]

L14 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 724793-73-1 CAPLUS
CN Butanamide, N-[[[(5S)-3-{4'-[(5S)-5-{(acetylamino)methyl}-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-2-amino-4-(methylthio)-, (2R)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 724793-72-0
CMF C27 H31 F2 N5 O6 S


Absolute stereochemistry.

L14 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CM 1

CRN 724793-67-3
CMF C25 H27 F2 N5 O6

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 724793-71-9 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[[[(5S)-3-{4'-[(5S)-5-{(acetylamino)methyl}-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-, (2R)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 724793-70-8
CMF C27 H29 F2 N5 O6

Absolute stereochemistry.

L14 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 724793-74-2 CAPLUS
CN Acetamide, N,N'-[[[(5S)-2-oxo-3,5-oxazolidinediylmethylene]bis- (9CI) (CA INDEX NAME)]


Absolute stereochemistry.



RN 724793-77-5 CAPLUS
CN Acetamide, 2-amino-N-[4,4'-bis[(5S)-5-{(acetylamino)methyl}-2-oxo-3-oxazolidinyl]-2,6-difluoro[1,1'-biphenyl]-3-yl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

L14 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 oxazolidinyl-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinylmethylamino)-1-[(1,1-dimethylethoxy)methyl]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 627542-07-8 CAPLUS
 CN 11-Oxa-2,4,9-triazatridec-2-enoic acid, 8-[[[(5S)-3-[4'-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinylmethylamino]carbonyl]-3-[[[(1,1-dimethylethoxy)methylamino]-12,12-dimethyl-10-oxo-, 1,1-dimethylethyl ester, (8S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



L14 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 Absolute stereochemistry.

PAGE 1-A



PAGE 1-B


NHAc

RN 627542-17-0 CAPLUS
 CN Acetamide, N-[[[(5S)-3-[4'-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinylmethylamino]carbonyl]-3-[[[(1,1-dimethylethoxy)methylamino]-12,12-dimethyl-10-oxo-, 1,1-dimethylethyl ester, (8S)- (9CI) (CA INDEX NAME)

CM 1


CRN 627542-16-9
 CMF C24 H25 F2 N5 O6

Absolute stereochemistry.



L14 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


PAGE 1-B




RN 627542-12-5 CAPLUS
 CN Carbamic acid, 4-[[[(5S)-3-[4'-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinylmethylamino]-3-hydroxy-4-oxobutyl]-, (4-methoxyphenyl)methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 627542-15-8 CAPLUS
 CN Carbamic acid, 2-[[[(5S)-3-[4'-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinylmethylamino]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L14 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CM 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 627542-22-7 CAPLUS
 CN Carbamic acid, 1-[[[(5S)-3-[4'-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinylmethylamino]carbonyl]-1,2-ethanediyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

NHAc


RN 627542-26-1 CAPLUS
 CN Propanoic acid, 3-[[[(5S)-3-[4'-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinylmethylamino]-3-oxo-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 627542-28-3 CAPLUS
 CN Carbamic acid, [(2,2'-difluoro[1,1'-biphenyl]-4,4'-diyl)bis[(5S)-2-oxo-3,5-oxazolidinediyl)methylene]]bis-, bis(1,1-dimethylethyl) ester (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.




RN 627542-37-4 CAPLUS
 CN Carbamic acid, [(2,2'-difluoro[1,1'-biphenyl]-4,4'-diyl)bis[(5S)-2-oxo-3,5-oxazolidinediyl)methyleneimino(2-oxo-2,1-ethanediy)]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 627542-40-9 CAPLUS
 CN Acetamide, N,N'-[(2,2'-difluoro[1,1'-biphenyl]-4,4'-diyl)bis[(5S)-2-oxo-3,5-oxazolidinediyl)methylene]]bis[2-amino-, mono(trifluoroacetate) (9CI)
 (CA INDEX NAME)


CH 1

CRN 627542-39-6

CMF C24 H26 F2 N6 O6

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

NH2

CH 2

CRN 76-05-1


CMF C2 H F3 O2




RN 627542-42-1 CAPLUS
 CN Carbamic acid, [(5S)-3-[4'-[(5S)-5-[[[(1,1-dimethylethoxy)carbonyl]amino]acetyl]amino]methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinylmethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 627542-45-4 CAPLUS
 CN Acetamide, 2-amino-N-[[[(5S)-3-[4'-[(5S)-5-(aminomethyl)-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinylmethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CH 1

CRN 627542-44-3

CMF C22 H23 F2 N5 O5

Absolute stereochemistry.

L14 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 627542-48-7 CAPLUS
CN 2-Oxazolidinone, 3-[(2,2'-difluoro-4'-[(5R)-5-(methoxymethyl)-2-oxo-3-oxazolidinyl](1,1'-biphenyl)-4-yl]-5-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 627542-52-3 CAPLUS
CN Carbamic acid, [[(5S)-3-{4'-[(5R)-5-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-2-oxo-3-oxazolidinyl](1,1'-biphenyl)-4-yl]-5-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-, (5R)- (9CI) (CA INDEX NAME)]

L14 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 627542-70-5 CAPLUS
CN 2-Oxazolidinone, 3,3'-[(2,2'-difluoro[1,1'-biphenyl]-4,4'-diyl)bis[5-[(methylamino)methyl]-, (5S,5'S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)]

CM 1

CRN 627542-69-2
CMF C22 H24 F2 N4 O4

Absolute stereochemistry.




CM 2

CRN 76-05-1
CMF C2 H F3 O2

L14 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


y)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 627542-60-3 CAPLUS
CN Carbamic acid, [[(5S)-3-{4'-[(5S)-5-[(dimethylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)]

Absolute stereochemistry.



RN 627542-66-9 CAPLUS
CN Carbamic acid, [(2,2'-difluoro[1,1'-biphenyl]-4,4'-diyl)bis[(5S)-2-oxo-3,5-oxazolidinediyl)methylene]]bis[methyl-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)]


Absolute stereochemistry.

L14 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 627542-72-7 CAPLUS
CN Propanoic acid, 3-[[[(5S)-3-{4'-[(5S)-5-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]amino]-3-oxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)]

Absolute stereochemistry.




PAGE 1-A

PAGE 1-B

OBu-t


RN 627542-80-7 CAPLUS
CN Butanoic acid, (2,2'-dimethoxy[1,1'-biphenyl]-4,4'-diyl)bis[(5R)-2-oxo-3,5-oxazolidinediyl)methylene] ester (9CI) (CA INDEX NAME)]

Absolute stereochemistry.




RN 627542-81-8 CAPLUS
CN 2-Oxazolidinone, 3,3'-(2,2'-dimethoxy[1,1'-biphenyl]-4,4'-diyl)bis[5-(hydroxymethyl)-, (5R,5'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 627542-82-9 CAPLUS
CN 2-Oxazolidinone, 3,3'-(2,2'-dimethoxy[1,1'-biphenyl]-4,4'-diyl)bis[5-[(methylsulfonyl)oxy]methyl]-, (5R,5'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 627542-84-1 CAPLUS
CN 2-Oxazolidinone, 3,3'-(2,2'-dimethoxy[1,1'-biphenyl]-4,4'-diyl)bis[5-(azidomethyl)-, (5R,5'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 627542-85-2 CAPLUS
CN 2-Oxazolidinone, 3,3'-(2,2'-dimethoxy[1,1'-biphenyl]-4,4'-diyl)bis[5-(aminomethyl)-, (5S,5'S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 627542-87-4 CAPLUS
CN 2-Oxazolidinone, 5-(azidomethyl)-3-[4'-[(5R)-5-(hydroxymethyl)-2-oxo-3-oxazolidinyl]-2,2'-dimethoxy[1,1'-biphenyl]-4-yl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 627542-89-6 CAPLUS
CN Acetamide, N-[[[(5S)-3-[4'-[(5R)-5-[(acetyloxy)methyl]-2-oxo-3-oxazolidinyl]-2,2'-dimethoxy[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 627542-95-4 CAPLUS
CN 1H-Indole-1,3(2H)-dione, 2-[[[(5S)-3-[2,2'-difluoro-4'-[(5R)-5-[(methoxymethoxy)methyl]-2-oxo-3-oxazolidinyl]methyl]-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-A

PAGE 1-B

OMe


RN 627542-96-5 CAPLUS
CN 2-Oxazolidinone, 5-(aminomethyl)-3-[2,2'-difluoro-4'-[(5R)-5-[(methoxymethoxy)methyl]-2-oxo-3-oxazolidinyl]methyl]-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 627542-97-6 CAPLUS
CN Acetamide, N-[[[(5S)-3-[2,2'-difluoro-4'-[(5R)-5-[(methoxymethoxy)methyl]-2-oxo-3-oxazolidinyl]methyl]-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 501939-75-9P 501939-79-3P 627541-95-1P
 627541-96-2P 627541-98-4P 627542-00-1P
 627542-01-2P 627542-02-3P 627542-04-5P
 627542-05-6P 627542-06-7P 627542-09-0P
 627542-10-3P 627542-11-4P 627542-13-6P
 627542-14-7P 627542-16-9P 627542-18-1P
 627542-19-2P 627542-20-5P 627542-21-6P
 627542-23-8P 627542-24-9P 627542-25-0P
 627542-27-2P 627542-31-8P 627542-32-9P
 627542-34-1P 627542-36-3P 627542-39-6P
 627542-44-3P 627542-46-5P 627542-50-1P
 627542-54-5P 627542-55-6P 627542-57-8P
 627542-63-6P 627542-64-7P 627542-69-2P
 627542-71-6P 627542-73-8P 627542-74-9P
 627542-75-0P 627542-76-1P 627542-77-2P
 627542-78-3P 627542-79-4P 627542-83-0P
 627542-86-3P 627542-88-5P 627542-90-9P
 627542-98-7P 627542-99-8P 627543-00-4P
 627543-01-5P 627543-02-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of bisoxoxazolidinyl)biphenyl deriva. as antibacterial


agents)

RN 501939-75-9 CAPLUS
 CN Acetamide, N,N'-[(2,2'-difluoro[1,1'-biphenyl]-4,4'-diyl)bis[(5S)-2-oxo-3,5-oxazolidinediyl]methylene]bis- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


RN 627541-96-2 CAPLUS
 CN Carbamic acid, [(5S)-3-[4'-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 627541-98-4 CAPLUS
 CN Acetamide, N-[(5S)-3-[2,2'-difluoro-4'-[(5S)-2-oxo-5-[(1-thioxoethyl)amino)methyl]-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 627542-00-1 CAPLUS
 CN Propanamide, N-[(5S)-3-[4'-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]methyl]-2-amino-3-hydroxy-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Absolute stereochemistry.




RN 501939-79-3 CAPLUS
 CN 2-Oxazolidinone, 3,3'-(2,2'-difluoro[1,1'-biphenyl]-4,4'-diyl)bis[5-(hydroxymethyl)-, (5R,5'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 627541-95-1 CAPLUS
 CN Acetamide, N-[(5S)-3-[4'-[(5R)-5-[(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 627542-01-2 CAPLUS
 CN Propanamide, N-[(5S)-3-[4'-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]methyl]-2-amino-3-hydroxy-, (2S)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 627542-00-1
 CMF C25 H27 F2 N5 O7

Absolute stereochemistry.




CM 2

CRN 76-05-1
 CMF C2 H F3 O2



RN 627542-02-3 CAPLUS
 CN Acetamide,
 N-[[[(5S)-3-(4'-[(5S)-5-[(aminoiminomethyl)amino]methyl]-2-oxo-3-oxazolidinyl)-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 627542-04-5 CAPLUS
 CN 1H-Imidazole-1-carboxylic acid, 5-[(2S)-3-[[[(5S)-3-(4'-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl)-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]amino]-2-[[[(1,1-dimethylethoxy)carbonyl]amino]-3-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L14 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 oxo-3-oxazolidinyl)-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-α-amino-, (αS)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1
 CRN 627542-05-6
 CMF C28 H29 F2 N7 O6

Absolute stereochemistry.



PAGE 1-B

NHAc


CM 2
 CRN 76-05-1
 CMF C2 H F3 O2



RN 627542-09-0 CAPLUS
 CN Pentanamide, N-[[[(5S)-3-(4'-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl)-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-2-amino-5-[(aminoiminomethyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

NHAc

RN 627542-05-6 CAPLUS
 CN 1H-Imidazole-4-propanamide,
 N-[[[(5S)-3-(4'-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl)-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-α-amino-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B

NHAc

RN 627542-06-7 CAPLUS
 CN 1H-Imidazole-4-propanamide,
 N-[[[(5S)-3-(4'-[(5S)-5-[(acetylamino)methyl]-2-

PAGE 1-A




PAGE 1-B

NHAc

RN 627542-10-3 CAPLUS
 CN Pentanamide, N-[[[(5S)-3-(4'-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl)-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-2-amino-5-[(aminoiminomethyl)amino]-, (2S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1
 CRN 627542-09-0
 CMF C28 H34 F2 N8 O6

Absolute stereochemistry.



PAGE 1-A

NHAc

CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 627542-11-4 CAPLUS
 CN D-Glucopyranuronamide,
 N-[(5S)-3-[4'-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-4-amino-2-hydroxy-, (2S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 627542-13-6 CAPLUS
 CN Butanamide, N-[(5S)-3-[4'-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-4-amino-2-hydroxy-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 627542-16-9 CAPLUS
 CN Acetamide, N-[(5S)-3-[4'-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-2-amino- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 627542-18-1 CAPLUS
 CN Acetamide, N-[(5S)-3-[4'-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-2-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 627542-19-2 CAPLUS
 CN 1-Cyclohexene-1-carboxamide,
 N-[(5S)-3-[4'-[(5S)-5-[(acetylamino)methyl]-




RN 627542-14-7 CAPLUS
 CN Butanamide, N-[(5S)-3-[4'-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-4-amino-2-hydroxy-, (2S)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 627542-13-6

CMF C26 H29 F2 N5 O7

Absolute stereochemistry.




CM 2

CRN 76-05-1


CMF C2 H F3 O2

Absolute stereochemistry.




RN 627542-20-5 CAPLUS
 CN Propanamide, N-[(5S)-3-[4'-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-2,3-dihydroxy-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 627542-21-6 CAPLUS
 CN 1H-Imidazole-4-carboxamide,
 N-[(5S)-3-[4'-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 627542-23-8 CAPLUS
 CN Propanamide, N-[[[(5S)-3-[(4'-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-2,3-diamino- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 627542-24-9 CAPLUS
 CN Propanamide, N-[[[(5S)-3-[(4'-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-2,3-diamino-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 627542-23-8
 CMF C25 H28 F2 N6 O6


Absolute stereochemistry.

Absolute stereochemistry.



RN 627542-31-8 CAPLUS
 CN 2-Oxazolidinone, 3,3'-(2,2'-difluoro[1,1'-biphenyl]-4,4'-diyl)bis[5-(aminomethyl)-, (5S,5'S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 627542-32-9 CAPLUS
 CN 2-Oxazolidinone, 3,3'-(2,2'-difluoro[1,1'-biphenyl]-4,4'-diyl)bis[5-(aminomethyl)-, (5S,5'S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 627542-31-8
 CMF C20 H20 F2 N4 O4

Absolute stereochemistry.




CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 627542-25-0 CAPLUS
 CN 2-Oxazolidinone, 5-[(acetyloxy)methyl]-3-[2,2'-difluoro-4'-[(5R)-5-(hydroxymethyl)-2-oxo-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 627542-27-2 CAPLUS
 CN Propanoic acid, 3-[[[(5S)-3-[(4'-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]amino]-3-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 627542-34-1 CAPLUS
 CN Acetamide, N-[[[(5S)-3-[(2,2'-difluoro-4'-[(5S)-5-[[[methylsulfonyl]amino]methyl]-2-oxo-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 627542-36-3 CAPLUS
 CN 2-Oxazolidinone, 3,3'-(2,2'-difluoro[1,1'-biphenyl]-4,4'-diyl)bis[5-(methoxymethyl)-, (5R,5'R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 627542-39-6 CAPLUS
CN Acetamide, N,N'-[(2,2'-difluoro[1,1'-biphenyl]-4,4'-diyl)bis[(5S)-2-oxo-3,5-oxazolidinediyl]methylene]bis[2-amino- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

NH2


RN 627542-44-3 CAPLUS
CN Acetamide, 2-amino-N-[(5S)-3-[4'-[(5S)-5-(aminomethyl)-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 627542-54-5 CAPLUS
CN 2-Oxazolidinone, 5-(aminomethyl)-3-[2,2'-difluoro-4'-[(5R)-5-(hydroxymethyl)-2-oxo-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 627542-55-6 CAPLUS
CN 2-Oxazolidinone, 5-(aminomethyl)-3-[2,2'-difluoro-4'-[(5R)-5-(hydroxymethyl)-2-oxo-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-, (5S)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 627542-54-5
CMF C20 H19 F2 N3 O5

Absolute stereochemistry.




RN 627542-46-5 CAPLUS
CN Acetamide, N-[(5S)-3-[4'-[(5S)-5-[(dimethylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 627542-50-1 CAPLUS
CN 2-Oxazolidinone, 3-[2,2'-difluoro-4'-[(5R)-5-(hydroxymethyl)-2-oxo-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-5-(methoxymethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 627542-57-8 CAPLUS
CN 2-Oxazolidinone, 3,3'-(2,2'-difluoro[1,1'-biphenyl]-4,4'-diyl)bis[5-[(dimethylamino)methyl]-, (5S,5'S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 627542-63-6 CAPLUS
CN 2-Oxazolidinone, 5-(aminomethyl)-3-[4'-[(5S)-5-[(dimethylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 627542-64-7 CAPLUS
CN 2-Oxazolidinone, 5-(aminomethyl)-3-[(4'-[(5S)-5-[(dimethylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl)-, (5S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 627542-63-6
CMF C22 H24 F2 N4 O4

Absolute stereochemistry.




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 627542-69-2 CAPLUS
CN 2-Oxazolidinone, 3,3'-(2,2'-difluoro[1,1'-biphenyl]-4,4'-diyl)bis[5-(methylamino)methyl]-, (5S,5'S)- (9CI) (CA INDEX NAME)




RN 627542-74-9 CAPLUS
CN Propanoic acid, 3-[[[(5S)-3-[(4'-[(5S)-5-(aminomethyl)-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl)-2-oxo-5-oxazolidinyl)methyl]amino]-3-oxo-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

INDEX NAME)

CM 1

CRN 627542-73-8
CMF C23 H22 F2 N4 O7


Absolute stereochemistry.



CM 2


CRN 76-05-1
CMF C2 H F3 O2

Absolute stereochemistry.



RN 627542-71-6 CAPLUS
CN Acetamide, N,N'-[(2,2'-difluoro[1,1'-biphenyl]-4,4'-diyl)bis[(5S)-2-oxo-3,5-oxazolidinediyl)methylene]]bis[N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 627542-73-8 CAPLUS
CN Propanoic acid, 3-[[[(5S)-3-[(4'-[(5S)-5-(aminomethyl)-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl)-2-oxo-5-oxazolidinyl)methyl]amino]-3-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 627542-75-0 CAPLUS
CN Acetamide, N,N'-[(2,2'-difluoro[1,1'-biphenyl]-4,4'-diyl)bis[(5S)-2-oxo-3,5-oxazolidinediyl)methylene]]bis[2-(acetylamino)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-A

PAGE 1-B

NHAc


RN 627542-76-1 CAPLUS
CN Acetamide, 2-(acetylamino)-N-[[[(5S)-3-[(4'-[(5S)-5-(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl)-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 627542-77-2 CAPLUS
CN Acetamide, N,N'-[(2,2'-difluoro[1,1'-biphenyl]-4,4'-diyl)bis[(5S)-2-oxo-3,5-oxazolidinediyl]methylene]bis[2-(dimethylamino)- (9CI) (CA INDEX NAME)]

Absolute stereochemistry.



RN 627542-79-4 CAPLUS
CN Acetamide, N-[(5S)-3-[2,2'-difluoro-4'-[(5S)-5-(1H-imidazol-1-ylmethyl)-2-oxo-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 627542-83-0 CAPLUS
CN 2-Oxazolidinone, 3-[2,2'-dimethoxy-4'-[(5R)-5-[(methylsulfonyl)oxy]methyl]-2-oxo-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-5-(hydroxymethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A

PAGE 1-B


-NMe2

RN 627542-78-3 CAPLUS
CN Acetamide, N-[(5S)-3-[4'-[(5S)-5-(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]methyl]-2-(dimethylamino)- (9CI) (CA INDEX NAME)




RN 627542-86-3 CAPLUS
CN Acetamide, N,N'-[(2,2'-dimethoxy[1,1'-biphenyl]-4,4'-diyl)bis[(5S)-2-oxo-3,5-oxazolidinediyl]methylene]bis- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 627542-90-9 CAPLUS
CN Acetamide, N-[(5S)-3-[4'-[(5R)-5-(hydroxymethyl)-2-oxo-3-oxazolidinyl]-2,2'-dimethoxy[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 627542-98-7 CAPLUS
CN Acetamide, N-[(5S)-3-[2,2'-difluoro-4'-[(5R)-5-(hydroxymethyl)-2-oxo-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 627542-88-5 CAPLUS
CN 2-Oxazolidinone, 5-(aminomethyl)-3-[4'-[(5R)-5-(hydroxymethyl)-2-oxo-3-oxazolidinyl]-2,2'-dimethoxy[1,1'-biphenyl]-4-yl]-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L14 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)


RN 627542-99-8 CAPLUS
CN Acetamide,
N-[(5S)-3-[2,2'-difluoro-4'-[(5S)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinylmethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 627543-00-4 CAPLUS
CN Acetamide, N-[(5S)-3-[4'-[(5S)-5-(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinylmethyl]-2-[(aminoiminomethyl)amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 627543-01-5 CAPLUS
CN Acetamide,
N-[(5S)-3-[2,2'-difluoro-4'-[(5R)-5-[(3-isoxazolyloxy)methyl]-2-oxo-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinylmethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L14 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



RN 627543-02-6 CAPLUS
CN Acetamide,
N-[(5S)-3-[2,2'-difluoro-4'-[(5R)-2-oxo-5-[(1,2,5-thiadiazol-3-yl)oxy)methyl]-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinylmethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



duplicate 8/4

L14 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)

ACCESSION NUMBER: 2003:221667 CAPLUS
DOCUMENT NUMBER: 138:238171
TITLE: Preparation of oxazolidinones and/or isoxazolinones as antibacterial agents
INVENTOR(S): Gravescock, Michael Barry; Hales, Neil James; Swain, Michael Lingard; Hauck, Sheila Irene; Mills, Stuart Dennett
PATENT ASSIGNEE(S): AstraZeneca AB, Swed.; AstraZeneca UK Limited
SOURCE: PCT Int. Appl., 127 pp.
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003022824	A1	20030320	WO 2002-GB4120	20020909
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TG, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2459766	AA	20030320	CA 2002-2459766	20020909
EP 1427711	A1	20040616	EP 2002-765019	20020909
EP 1427711	B1	20050713		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002012458	A	20040109	BR 2002-12458	20020909
JP 200507386	T2	20050317	JP 2003-526899	20020909
US 2005107435	A1	20050519	US 2003-489266	20020909
NZ 531621	A	20050624	NZ 2002-531621	20020909
CN 1639136	A	20050713	CN 2002-822327	20020909
AT 299502	E	20050715	AT 2002-765019	20020909
PT 1427711	T	20051130	PT 2002-765019	20020909
ES 2244802	T3	20051216	ES 2002-2765019	20020909
ZA 2004001888	A	20050418	ZA 2004-1888	20040308
NO 2004001428	A	20040608	NO 2004-1428	20040405
HK 1065789	A1	20051230	HK 2004-108506	20041029
			GB 2001-21942	A 20010911
PRIORITY APPLN. INFO.:			GB 2002-15420	A 20020704
			WO 2002-GB4120	W 20020909

OTHER SOURCE(S): MARPAT 138:238171
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Oxazolidinones and isoxazolinones (shown as 1: variables defined below; e.g.

L14 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)


(5S,5S')-N-[3-(4'-[(5-(acetylamino)methyl)-2-oxooxazolidin-3-yl]-2,2'-difluorobiphenyl-4-yl)-2-oxooxazolidin-5-ylmethyl]acetamide (shown as II), or a pharmaceutically-acceptable salt, or an in-vivo-hydrolyzable ester thereof, which useful as antibacterial agents, processes for their manuf. and pharmaceutical compns. contg. them are described. For I: C is for example III, IV, V; wherein A and B = 2-oxooxazolidin-3-yl, 2-isoxazolin-3-yl; R2a to R2b = H and F; R1a and R1b =, for example, hydroxy, -NHC(=O)R4, NH(HET-1) and HET-2; wherein W is O or S; R4 is, for example, H, amino, (1-4C)alkyl; HET-1 is, for example, a C-linked 5-membered heteroaryl ring; HET-2 is, for example, an N-linked 5-membered, fully or partially unsatd. heterocyclic ring. I have good activity against a broad range of Gram-pos. pathogens including organisms known to be resistant to most commonly used antibiotics, together with activity against fastidious Gram neg. pathogens such as H. influenzae, M. catarrhalis, Mycoplasma and Chlamydia strains. The min. inhibitory concns. of II for methicillin sensitive and quinolone sensitive Staphylococcus aureus, methicillin resistant and quinolone resistant Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae, and Moraxella catarrhalis are 0.25, 0.5, 0.06, 0.13, 2.0 and 0.5 µg/mL, resp. Preps. of 64 examples of I and many intermediates are included. For example, I was prepd. as follows: (5S)-N-[3-(3-fluoro-4-iodophenyl)-2-oxooxazolidin-5-yl]methyl]acetamide (0.4 mmol) and Bu4NBr (0.4 mmol) were stirred in a mixt. of DMF (0.5 mL) and NEt3 (2 mmol), and degassed by bubbling N. Pd(II) acetate (0.04 mmol) was added, and the whole heated at 70° for 18 h. Workup gave the desired product (47 mg). Nine examples of pharmaceutical dosage forms are tabulated.

IT 501939-76-0P, Acetic acid (5R,5'R)-3-[4'-[(5-acetoxymethyl)-2-

oxooxazolidin-3-yl]-2,2'-difluorobiphenyl-4-yl]-2-oxooxazolidin-5-ylmethyl ester 501940-31-4P, (5R)-5-[[[tert-Butyldimethylsilyl]oxy]methyl]-3-[4'-[(5R)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-1,3-oxazolidin-3-yl]-1,1'-biphenyl-4-yl]-1,3-oxazolidin-2-one
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BCT (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of oxazolidinones and/or isoxazolinones as antibacterial agents)


RN 501939-76-0 CAPLUS
CN 2-Oxazolidinone, 3,3'-(2,2'-difluoro[1,1'-biphenyl]-4,4'-diyl)bis[5-(acetyloxy)methyl]-, (5R,5'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501940-31-4 CAPLUS
CN 2-Oxazolidinone, 5-[[[1,1-dimethylethyl]dimethylsilyl]oxy]methyl]-3-[4'-{(5R)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl}[1,1'-biphenyl]-4-yl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 501939-75-9P, (5S,5'S)-N-[[3-[4'-[5-[(Acetylamino)methyl]-2-oxooxazolidin-3-yl]-2,2'-difluorobiphenyl-4-yl]-2-oxooxazolidin-5-yl]methyl]acetamide 501939-79-3P, (5R,5'R)-4,4'-Bis[5-(hydroxymethyl)-2-oxooxazolidin-3-yl]-2,2'-difluorobiphenyl 501939-80-6P, (5S,5'S)-4,4'-Bis[5-[(isoxazol-3-ylamino)methyl]-2-oxooxazolidin-3-yl]-2,2'-difluorobiphenyl 501939-93-1P, (5R,5'R)-4,4'-Bis[5-(1H-1,2,3-triazol-1-yl)methyl]-2-oxooxazolidin-3-yl]-2,2'-difluorobiphenyl 501940-25-6P, (5S,5'S)-N-[[3-[4'-[5-[(Acetylamino)methyl]-2-oxooxazolidin-3-yl]-1,1'-biphenyl-4-yl]-2-oxooxazolidin-5-yl]methyl]acetamide 501940-26-7P,

(5R,5'R)-3-(2,2'-Difluoro-4'-[5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-1,3-oxazolidin-3-yl]-1,1'-biphenyl-4-yl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 501940-29-0P, (5R)-5-(Hydroxymethyl)-3-[4'-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-3-yl]-1,1'-biphenyl-4-yl]-1,3-oxazolidin-2-one 501940-33-6P 501940-34-7P, N-[[[5S]-3-[4'-[(5R)-5-[[tert-Butyldimethylsilyl]oxy]methyl]-2-oxo-1,3-oxazolidin-3-yl]-2,2'-



RN 501939-93-1 CAPLUS
CN 2-Oxazolidinone, 3,3'-(2,2'-difluoro[1,1'-biphenyl]-4,4'-diyl)bis[5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R,5'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501940-25-6 CAPLUS
CN Acetamide, N,N'-[[1,1'-biphenyl]-4,4'-diylbis[[5S]-2-oxo-3,5-oxazolidinediyl]methylene]bis-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L14 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)
difluoro-1,1'-biphenyl-4-yl]-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide 501940-37-0P, (5R)-3-[2-Fluoro-4'-[(5R)-5-(hydroxymethyl)-2-oxo-1,3-oxazolidin-3-yl]-1,1'-biphenyl-4-yl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 501940-38-1P, (5R)-5-(Hydroxymethyl)-3-[4'-[(5R)-5-[(4-methyl-1H-1,2,3-triazol-1-

yl)methyl]-2-oxo-1,3-oxazolidin-3-yl]-1,1'-biphenyl-4-yl]-1,3-oxazolidin-2-one
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; prepn. of oxazolidinones and/or isoxazoles as antibacterial agents)


RN 501939-75-9 CAPLUS
CN Acetamide, N,N'-[(2,2'-difluoro[1,1'-biphenyl]-4,4'-diyl)bis[[5S]-2-oxo-3,5-oxazolidinediyl]methylene]bis-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501939-79-3 CAPLUS
CN 2-Oxazolidinone, 3,3'-(2,2'-difluoro[1,1'-biphenyl]-4,4'-diyl)bis[5-(hydroxymethyl)-, (5R,5'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501939-80-6 CAPLUS
CN 2-Oxazolidinone, 3,3'-(2,2'-difluoro[1,1'-biphenyl]-4,4'-diyl)bis[5-(isoxazolylamino)methyl]-, (5S,5'S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501940-26-7 CAPLUS
CN 2-Oxazolidinone, 3,3'-(2,2'-difluoro[1,1'-biphenyl]-4,4'-diyl)bis[5-(4-methyl-1H-1,2,3-triazol-1-ylmethyl)-, (5R,5'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501940-29-0 CAPLUS
CN 2-Oxazolidinone, 3-[4'-[(5R)-5-(hydroxymethyl)-2-oxo-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501940-33-6 CAPLUS
 CN 2-Oxazolidinone, 5-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-3-[2'-fluoro-4'-[(5R)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501940-34-7 CAPLUS
 CN Acetamide,
 N-[[[(5S)-3-(4'-[(5R)-5-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501940-37-0 CAPLUS
 CN 2-Oxazolidinone, 3-[2-fluoro-4'-[(5R)-5-(hydroxymethyl)-2-oxo-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501940-38-1 CAPLUS
 CN 2-Oxazolidinone, 5-(hydroxymethyl)-3-[4'-[(5R)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 501939-81-7P, N-(5R,5'R)-[[3-[4'-[5-[[tert-butoxycarbonyl(isoxazol-3-yl)amino]methyl]-2-oxooxazolidin-3-yl]-2,2'-difluoro-1,1'-biphenyl-4-yl]-2-oxooxazolidin-5-yl)methyl]-N-(isoxazol-3-yl)carbamate tert-butyl ester
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of oxazolidinones and/or isoxazolines as antibacterial agents)

RN 501939-81-7 CAPLUS
 CN Carbamic acid, [(2,2'-difluoro[1,1'-biphenyl]-4,4'-diyl)bis[(5R)-2-oxo-3,5-oxazolidinediyl]methylene]bis[3-isoxazolyl]-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	49.21	551.12
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-6.75	-6.75

STN INTERNATIONAL LOGOFF AT 08:01:10 ON 18 MAY 2006

L13 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS ON STN

ACCESSION NUMBER: 2003:221667 CAPLUS
DOCUMENT NUMBER: 138:238171
TITLE: Preparation of oxazolidinones and/or isoxazolinones as antibacterial agents
INVENTOR(S): Gravestock, Michael Barry; Hales, Neil James; Swain, Michael Lingard; Hauck, Sheila Irene; Mills, Stuart; Dennett
PATENT ASSIGNEE(S): AstraZeneca AB, Swed.; AstraZeneca UK Limited
SOURCE: PCT Int. Appl., 127 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE
WO 2003022824 A1 20030126 WO 2002-GB4120 20020909
W: AE, AG, AL, AM, AT, AU, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZH, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
CA 2459766 AA 20030320 CA 2002-2459766 20020909
EP 1427711 A1 20040616 EP 2002-765019 20020909
EP 1427711 B1 20050713
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, TE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK
BR 2002012458 A 20041019 BR 2002-12458 20020909
JP 200507386 T2 20050317 JP 2003-526899 20020909
US 2005107435 A1 20050519 US 2003-489266 20020909
NZ 531621 A 20050624 NZ 2002-531621 20020909
CN 1639136 A 20050713 CN 2002-822327 20020909
AT 299502 E 20050715 AT 2002-765019 20020909
PT 1427711 T 20051130 PT 2002-765019 20020909
ES 2244802 T3 20051216 ES 2002-2765019 20020909
ZA 2004001888 A 20050418 ZA 2004-1888 20040308
NO 2004001428 A 20040608 NO 2004-1428 20040405
HK 1065789 A1 20051230 HK 2004-108506 20041029
GB 2001-21942 A 20010911
GB 2002-15420 A 20020704
WO 2002-GB4120 W 20020909


OTHER SOURCE(S): MARPAT 138:238171
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB Oxazolidinones and isoxazolinones (shown as I: variables defined below:
e.g.

L13 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)

RN 501940-08-5 CAPLUS
CN Isoxazole,
3,3'-(2,2'-difluoro[1,1'-biphenyl]-4,4'-diyl)bis[4,5-dihydro-5-
[[4-methyl-1H-1,2,3-triazol-1-yl)methyl]] (9CI) (CA INDEX NAME)



RN 501940-16-5 CAPLUS
CN 5-Isoxazolemethanol,
3,3'-(2,2'-difluoro[1,1'-biphenyl]-4,4'-diyl)bis[4,5-
dihydro- (9CI) (CA INDEX NAME)



IT 501940-24-5P, 3-[4'-[5-[[[(tert-Butyldimethylsilyl)oxy)methyl]-4,5-dihydroisoxazol-3-yl]-2,2'-difluoro-1,1'-biphenyl-4-yl]-5-[[[(tert-Butyldimethylsilyl)oxy)methyl]-4,5-dihydroisoxazole
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of oxazolidinones and/or isoxazolinones as antibacterial agents)
RN 501940-24-5 CAPLUS
CN Isoxazole, 3,3'-(2,2'-difluoro[1,1'-biphenyl]-4,4'-diyl)bis[5-[[[(1,1-dimethylethyl)dimethylsilyl]oxy)methyl]-4,5-dihydro- (9CI) (CA INDEX NAME)


L13 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)
(5S,5S')-N-[3-(4'-(5-(acetylaminoethyl)-2-oxooxazolidin-3-yl)-2,2'-difluorobiphenyl-4-yl)-2-oxooxazolidin-5-ylmethyl]acetamide (shown as II), or a pharmaceutically-acceptable salt, or an in-vivo-hydrolyzable ester thereof, which useful as antibacterial agents, processes for their manuf. and pharmaceutical compns. contg. them are described. For I: C is for example III, IV, V, wherein A and B = 2-oxooxazolidin-3-yl, 2-isoxazolin-3-yl; R2a to R3b = H and F; R1a and R1b =, for example, hydroxy, -NHC(=O)R4, NH(HET-1) and HET-2; wherein W is O or S; R4 is, for example, H, amino, (1-4C)alkyl; HET-1 is, for example, a C-linked 5-membered heteroaryl ring; HET-2 is, for example, an N-linked 5-membered, fully or partially unsatd. heterocyclic ring. I have good activity against a broad range of Gram-pos. pathogens including organisms known to be resistant to most commonly used antibiotics, together with activity against fastidious Gram neg. pathogens such as H. influenzae, M. catarrhalis, Mycoplasma and Chlamydia strains. The min. inhibitory concns. of II for methicillin sensitive and quinolone sensitive Staphylococcus aureus, methicillin resistant and quinolone resistant Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae, and Moraxella catarrhalis are 0.25, 0.5, 0.06, 0.13, 2.0 and 0.5 µg/mL, resp. Preps. of 64 examples of I and many intermediates are included. For example, I was prepd. as follows: (5S)-N-[[3-(3-fluoro-4-iodophenyl)-2-oxooxazolidin-5-yl]methyl]acetamide (0.4 mmol) and Bu4NBr (0.4 mmol) were stirred in a mixt. of DMF (0.5 mL) and NEt3 (2 mmol), and degassed by bubbling N. Pd(II) acetate (0.04 mmol)

was added, and the whole heated at 70° for 18 h. Workup gave the desired product (47 mg). Nine examples of pharmaceutical dosage forms are tabulated.


IT 501940-05-2P, N-[[3-(2,2'-Difluoro-4'-(5-acetamidomethyl-4,5-dihydroisoxazol-3-yl)-1,1'-biphenyl-4-yl)-4,5-dihydroisoxazol-5-yl]methyl]acetamide 501940-08-5P, 1-[[3-(2,2'-Difluoro-4'-(5-(4-methyl-1H-1,2,3-triazol-1-yl)methyl)-4,5-dihydroisoxazol-3-yl)-1,1'-biphenyl-4-yl]-4,5-dihydroisoxazol-5-yl]methyl]-4-methyl-1H-1,2,3-triazole 501940-16-5P, [3-(2,2'-Difluoro-4'-(5-hydroxymethyl-4,5-dihydroisoxazol-3-yl)-1,1'-biphenyl-4-yl)-4,5-dihydroisoxazol-5-yl]methanol
RL: PRC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate: preparation of oxazolidinones and/or isoxazolinones as antibacterial agents)

RN 501940-05-2 CAPLUS
CN Acetamide,
N,N'-[(2,2'-difluoro[1,1'-biphenyl]-4,4'-diyl)bis[4,5-dihydro-3,5-isoxazolidiyl]methylene]]bis- (9CI) (CA INDEX NAME)



L13 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT